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1.1 Ion channels 
 
The flow of ions across the cell membrane is a crucial process for life: it provides 
nutrients, generates electrical signals, regulates cell volume, secretes electrolytes across 
epithelial layers (Hille, 2001). Ion channels, together with transporters and pumps are 
the main players to accomplish these physiological functions. Ion channels are proteins 
equipped with a hydrophilic pore traversing the entire lipid bilayer of the membrane of 
all prokaryotic and eukaryotic cells. They allow the transit through the membrane of 








, with a very high flow rate: up to 100 
million ions/s can flow through a single channel (Kandel, 2000). Two main factors 
distinguish ion channels from simple aqueous pores. The first is the ion selectivity, 
meaning that ion channels allow the passage exclusively (or with very high selectivity) 
of one ion rather than another. This is thought to be mediated by the selectivity filter 
region of the channel that preferentially interacts with and mediates the passage of the 
proper ion. The second important distinction is that the former are not always in open 
state. Events of opening and closure (or "gating") are continuously occurring and, 
depending on a specific stimulus, strictly regulated.  
The first insights into the structure and function of ion channels had been derived from 
molecular and structural biology studies as well as pioneering electrophysiological 
investigations. The first milestone in the latter field was achieved by Hodgkin and 
Huxley who in 1952, based on evidence provided by voltage clamp experiments, 
elaborated a series of mathematical models describing how ionic current generated by 
ion channels give rise to action potential in neurons (Hodgkin and Huxley, 1952). Later 
on, towards end of the 1970s, the field of electrophysiology was revolutionized by the 
invention of the patch-clamp technique, a powerful method that allows real time 
analysis of current flowing at the level of single channel molecule (Neher et al., 1978). 
About thirty years ago the first ion channel was cloned (Noda et al., 1983), and to date 
genes for most of the major classes of ion channels have been cloned and sequenced. 
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Moreover, after the first structure of a bacterial potassium channel obtained by X-ray 
crystallography (Doyle et al., 1998), several different channel structures are now 
available. Ion channels subunit sequences have also been extensively engineered 
through manipulation of their DNA sequence, providing hints about the function 
associated with the mutated DNA region.  
Based on data from various fields, we know that ion channels are generally 
macromolecular (oligomeric) complexes formed by assembly of several subunits. The 
majority of channels have three, four, or five homologous or identical α subunits 
arranged in circular symmetry, forming a single aqueous pore at their axial intersection 
(Fig. 1 A). In certain types of channels, additional accessory subunits are coupled to the 
ion conducting (α) subunits (Fig. 1 B). Ion channels possess many features typical of 
membrane proteins: they are synthesized and inserted into the membrane of the 
endoplasmic reticulum (ER), glycosylated in the Golgi, and transported and inserted 
into target membranes by membrane fusion processes (see section 1.2). 
The wide variety of ion channel structures is correlated with a large diversity regarding 
the main type of stimulus causing their opening: change in the voltage across the 
membrane (voltage-gated channels), mechanical stress (mechanically gated channels), 
or the binding of a ligand (ligand-gated channels). The ligand can be either an 
extracellular mediator, a neurotransmitter (transmitter-gated channels) or an 
intracellular mediator, such as an ion (ion-gated channels), or a nucleotide (nucleotide-
gated channels) (Alberts et al., 2002). The activity of many ion channels can be 
moreover modulated by post-translational modification like phosphorylation, 
dephosphorylation, ubiquitinylation, SUMOylation, palmitoylation and N-linked-
glycosilation. Mechanisms of alternative splicing (as will be described in section 1.5.2) 
as well as interaction of the α subunits of the channels with auxiliary (β or γ) subunits 
play a critical role expanding ion channel diversity and in the modulation of their 






Figure 1 Ion channels multisubunit architecture. (A) Ion channels can be formed by heterooligomers 
from distinct subunits (left), as homooligomers from a single type of subunit (middle), or from a single 
polypeptide chain organized into repeating motifs, where each motif behaves like one subunit (right). (B) 
Some channels contain auxiliary subunits (β or γ), which modulate the gating characteristics of the central 
core (figure modified from Kandel, 2001). 
 
To date, more than one hundred genes coding for several hundreds of different ion 
channels have been identified (Gabashvili et al., 2007). The need for classification of 
this plethora of molecules led to the elaboration of a numbering system for mammalian 
voltage-gated potassium channel (Chandy, 1991), then for voltage-gated calcium 
channels (Ertel et al., 2000) and for voltage-gated sodium channels (Goldin, 2002). 
However, a classification system widely accepted nowadays is based on the IUPHAR 
(International Union of basic and clinical Pharmacology) classification 
(http://www.iuphar-db.org), in which the products of gene families and superfamilies 
are named based on the chemical symbol of the main permeating ion (Na, K, or Ca) and 
with the principal physiological regulator depicted subscript (for example, a voltage 
activated potassium channel will be depicted with Kv) followed by a number indicating 
the gene subfamily and a decimal that separates the number assigned to specific channel 
isoforms. This classification system will be used wherever appropriate in this thesis.  
Overall, in recent years improved electrophysiological methods coupled with advanced 
molecular and structural biology techniques have provided a much more comprehensive 






1.1.1 The superfamily of voltage-gated channels 
 
As the name already suggests, voltage-gated channels are opened by changes in 
membrane potential. They all consist of four homologous motifs, each of them formed 
by six transmembrane segments (S1 to S6) containing a voltage sensor domain and a 
pore-forming domain (Fig. 2). The four pore-forming α domains converge to form the 
single central pore, whereas the four voltage sensors are placed laterally within the 
membrane lipid bilayer. The opening and establishment of ionic conductance requires 
that voltage-gated channels are provided with charges that would respond to voltage 
changes, as already postulated by Hodgkin and Huxley in 1952. Subsequently, the 
existence of the voltage sensor was demonstrated: it consists of a region within the S4 
transmembrane segment of each domain composed of repeated motifs of one positively 
charged residue followed by two hydrophobic residues, potentially creating a helical 
arrangement of positive charges through the membrane (Noda et al., 1984). 
Neutralization of the four positively charged residues in the S4 segment of domain I of 
the sodium channel by site-directed mutagenesis has major effects on the voltage 
dependence of activation (Stühmer et al., 1989). The movement of the voltage-sensor 
charged by changes of electric field across the membrane therefore alters the 
equilibrium between the closed and open states of the channel, thus controlling the ion 
flow. The passage of ions occurs through the pore region, situated between S5 and S6 
transmembrane segment of each domain. Voltage-gated channels show different ion 
selectivities for monovalent cations and are therefore classified as NaV, KV, and CaV 
channels.  
Apart from the similar backbone structure previously mentioned, the final structure of 
the voltage-gated channels show relevant differences between different families: in Nav 
channels, the four homologous α domains, (each of them formed by six transmembrane 
segments) are derived by a single, linear sequence connected by intracellular loops and 
associated with one or more auxiliary β-subunits, the latter required for normal kinetics 
and voltage dependence of gating (Catterall, 2000a). In the case of Cav, the pore-
forming α1 linear sequence is assembled together with a transmembrane, disulfide-
linked complex of α2 and δ subunits and an intracellular β subunit. In some cases, a 
transmembrane γ subunit is also found. Mutations in these subunits have a tremendous 
impact on expression level, voltage dependence and gating properties of the channels 
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(Catterall, 2000b). With forty known genes, voltage-gated potassium channels represent 
the largest superfamily of ion channels. Unlike voltage-gated calcium and sodium 
channels, the voltage-gated potassium channels encode in their primary sequence only a 
single α domain. The assembly of four α domains is primarily mediated by a region 
located within the intracellular hydrophilic amino-terminus (KV1) or carboxy-terminus, 
(as the case of KV7, KV10, KV11 and KV12 channels)(Jenke et al., 2003). This region is 
known as the tetramerization domain (Li et al., 1992). Homo- or heterotetramers 
(formed by different subunits within the same family) of α subunits form the functional 
voltage-gated potassium channel. β subunits can also interact with these types of 
channels, modulating their function (Catterall, 1995). In this regard, the tetramerization 





Figure 2 General architecture of a voltage-gated channel. Top shows the basic subunit (or domain in 




 channels). The gray background represents the lipid bilayer. The cylinders 
represent transmembrane segments. The region between S5 and S6 forms the pore. The voltage sensor 
part of the channel consists of the segments from S1 to S4. The + or - signs indicate charges involved in 
voltage sensing. In the bottom part, a schematic view of the channel from the outside showing the 






1.2 Trafficking of ion channels 
 
The intracellular trafficking of membrane proteins such as ion channels is a complex 
and highly regulated process. It involves both forward (towards the plasma membrane) 
and backward (internalization from the plasma membrane) transport. The journey starts 
when the nascent protein chain moves from the ER membrane bound ribosome into the 
ER lumen. Here the processes of folding and assembly occur, in a co-translational 
manner (Kosolapov and Deutsch, 2003). In most of the voltage-gated potassium 
channels (including KV10.1 channels) the ‘newborn’ protein may additionally undergo 
core-glycosylation at this phase (Napp et al., 2005, Steele et al., 2007). A pre-
synthesized oligosaccharide (Glc3MangGlcNAc2) is transferred to an asparagine (Asn) 
residue in the nascent peptide chain by the enzyme oligosaccharyltransferase (Kaplan et 
al., 1987). Core glycosylation generally occurs at the Asn residues in the sequon Asn-X-
Ser/Thr, (X is any amino acid except proline) (Kaplan et al., 1987). N-Linked 
glycosylation represents a common form of membrane protein processing that can 
profoundly affect protein expression, structure, and function. Defects in glycosylation 
may result in the generation of misfolded, aggregated proteins failing to reach a 
functional state.  
Quality control mechanisms at the ER, such as heat shock protein (Hsp) 70 and 90, and 
calnexin (Zerangue et al., 1999; Ficker et al., 2003; Steele et al., 2007; Staudacher et al., 
2010) ensure that only correctly folded, assembled channel proteins are exported from 
the ER to Golgi (Ellgaard and Helenius, 2001) whereas misfolded proteins are retained 
in the ER (aggregating with other misfolded proteins) and eventually targeted for 
degradation (Zerangue et al., 1999). In the Golgi, further processing of the channel 
protein like complex glycosylation occurs; the oligosaccharides gain complexity as 
proteins progress through the Golgi apparatus, resulting in complex, high-mannose, or 
hybrid oligosaccharides. From the Golgi network the complex glycosylated proteins are 
directed to the plasma membrane to be finally inserted within the lipid bilayer. 
Remarkably, ion channels do not simply traffic to any random area in the plasma 
membrane, but rather localize to specific cell surface domains (Steele et al., 2007). 
Membrane insertion process occurs by means of SNARE-mediated fusion of vesicles 
containing the ion channel protein with the plasmalemma. SNAREs are thought to 
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deform membranes, affecting the hydrophobic–hydrophilic boundary and directly 
inducing fusion (Jahn and Scheller, 2006). In order to ensure adequate cellular plasticity 
and homeostasis, ion channels expression at level of the cell surface is finely regulated. 
Channels undergo internalization and can either be recycled or degraded in proteasomes 
or lysosomes (Steele et al., 2007). 
 
 
1.3 Physiological and pathophysiological roles of ion channels 
 
Ion channels play important roles in diverse processes such as nerve and muscle 
excitation, hormone secretion, cell proliferation, sensory transduction, learning and 
memory, regulation of blood pressure, salt and water balance, fertilization and cell death 
(Ashcroft, 2006). In particular, voltage-gated potassium channels control cell 
excitability and set the resting potential, contributing to the origin and propagation of 
the action potential in neurons and other excitable cells. 
Ion channel dysfunctions can result in a large variety of diseases; to date, mutations in 
over 60 ion channel genes have been associated with human pathologies. The 
dysregulation of certain types of voltage-gated channels causing hyperexcitability may 
result in different pathologic phenotypes: epilepsy, occurring in central neurons; 
myotonia (prolonged muscle contraction) in skeletal muscle, arrhythmia when in the 
heart. Other example of pathologic phenotypes associated with ion channels are cystic 
fibrosis, hypertension, diabetes, and gastrointestinal disorders (Ashcroft, 2006). 
Increasing evidences suggest an involvement of ion channels in cell proliferation and 
cancer (see section 1.3.1). Given the important role of ion channels in many 
pathophysiological events, together with their structural heterogeneity and convenient 
transmembrane localization, these molecules represent an attractive target for 
pharmacologic therapies. Indeed, it is not surprising that currently more than 13% of all 
available pharmacologic therapies utilizes drugs having ion channels as their primary 




1.3.1 Role of ion channels in cell proliferation and cancer 
 
An emerging physiological and pathophysiological role of ion channels expression is 
their implication with cell proliferation (Wonderlin and Strobl, 1996; Pardo, 2004; 
Kunzelmann, 2005). Oscillation of membrane potential exerted by ion channels is 
required for progression of the cell cycle: the membrane potential in early G1 phase is 
depolarized and the transition from G1 to S phase during mitosis is accompanied by 
hyperpolarization of the membrane potential (Wonderlin et al., 1995). In this context, 
potassium channels expression, while inducing a shift of the membrane potential 
towards negative values, would provide the driving force required for calcium to enter 
the cell. Calcium is an important mediator of intracellular signals, implicated in the 
control of proliferation among other crucial processes in cell physiology (Lee et al., 
1993). Beside the calcium-mediated effect, another hypothesis about ion channel impact 
on proliferation relies on the regulation in cell volume mediated by chloride channels: 
changes in cell size would either favor the progression along the cell cycle, or commit 
the cell to undergo apoptosis (Lang et al., 2000). Moreover, inhibition of K
+
 channels 
may affect regulation of cytosolic pH and reduce proliferation by causing cellular 
acidification (Kunzelmann, 2005). The proliferative stimulus related to expression of 
potassium channels (KCa3.1 and KV1.3) is also crucial for lymphocyte B and T 
maturation and proliferation. These channels have been proposed as novel therapeutic 
targets for autoimmune disorders (Beeton et al., 2005). More interestingly, 
dysregulation of Ca
2+
-channels (in particular transient receptor potential - TRP -
channels), K
+
 channels (like KCa1.1, KCa3.1, KV1.3, KV10.1 and KV11.1) and Na
+
 
channels (like NaV1.5 and NaV1.7) all contribute to cancer progression, acting through a 
series of mechanisms, ranging from cell cycle and cell metabolism regulation, 
influencing the cell motility and capacity of invasion of tumor cells (Pedersen and 







1.4 KV10.1 channels 
 
KV10.1 (also named Eag1) is a member of the ether-à-go-go (eag) family of voltage 
activated potassium channels. The name eag was assigned to a mutant showing leg-
shaking in response to ether anesthesia in the fruit fly Drosophila melanogaster (Kaplan 
and Trout, 1969). Subsequent cloning of the gene revealed that KV10.1 encodes a 
voltage-gated potassium channel (Brüggemann et al., 1993). The human ortholog of 
Drosophila eag gene (KV10.1) was cloned in 1998: the gene is located at position 32.1–
32.3 of the long arm of human chromosome 1; it encodes eleven exons (Occhiodoro et 
al., 1998; Pardo et al., 1999) and it is translated into a protein of apparent molecular 
weight of ~130 kDa (Napp et al., 2005). To date, the eag family includes eight 
members: beside KV10.1, the closely related KV10.2 (eag2), the KV12 (elk) subfamily 
(elk1, elk2, elk3) and the KV11 (erg) proteins (erg1, erg2, erg3) have been identified. 
Similarly to the other KV superfamily members, KV10.1 shows the characteristic six 
transmembrane domains with long intracellular amino- and carboxyl- terminal regions, 
bearing several recognizable motifs. In the N-terminal domain, a Per-Arnt-Sim 
(PAS)/PAS associated C-terminal (PAC) domain and a binding site for calmodulin. 
Two binding sites for calmodulin, a cyclic nucleotide binding domain (cNBD), a 
nuclear localization signal (NLS) and a tetramerizing coiled-coil (TCC) domain in the 
carboxyl-terminus (Fig. 3). The binding sites for calmodulin modulate channel function 
(see below). The TCC domain is crucial for assembly in the tetrameric conformation 
typical of functional channels (Jenke et al., 2003; Ludwig et al., 1997). The functional 
roles of KV10.1 PAS/PAC (frequently named eag domain) and cNBD domains are still 
undisclosed. However, recent crystal structure analyses show that PAS/PAC and cNBD 
domains extensively interact; disruption of this interaction induced by mutations alters 
the gating properties of KV10.1 channels (Haitin et al., 2013). KV10.1 channels also 
undergo post-translational modifications: glycosylation sites are present on asparagine 
residues at positions 388 and 406 of the extracellular loop between S5 and S6 
transmembrane domains. Asn-388 seems to undergo only core glycosylation; 
additionally complex sugars are bound to Asn-406. Correct glycosylation is critical for 
the proper trafficking of the channel to the membrane, as well as for its correct function 
once the channel reached already the membrane (Napp et al., 2005). Regarding the 
channel trafficking, KV10.1 undergoes very rapid surface turnover (a given set of 
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membrane channels is getting internalized once during ~100 min), which controls the 
subcellular distribution and life cycle of the channel (Kohl et al., 2011). KV10.1 
channels are partitioned in different subdomains along the plasma membrane, and their 
activity varies depending on their distribution (Jiménez-Garduño et al., 2013). This 
could provide a functional correlate to the finding that endogenous KV10.1 channels 




Figure 3 Putative structure of a subunit of the voltage-gated potassium channel KV10.1. Each 
subunit is formed by six transmembrane domains; the voltage sensor is located between S1 and S4, and 
the pore between S5 and S6. The branches along the third extracellular loop (E3) represent glycosylation 
sites. Two long intracytoplasmic regions containing several binding motifs are also highlighted. 
 
A second KV10.1 transcript (called KV10.1b, to distinguish it from the originally cloned, 
KV10.1a) has been cloned from mouse and human brain, and bovine retina. KV10.1b has 
an insertion of 27 amino acids in the extracellular linker between transmembrane 
segments S3 and S4 (Warmke and Ganetzky, 1994; Frings et al., 1998; Pardo et al., 
1999). As far as determined, KV10.1a and KV10.1b share expression pattern and 
electrophysiological properties. Additional KV10.1 transcripts derived from events of 
alternative splicing have been recently detected in human brain and cancer cell lines 
(see section 1.5.3). 
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In a physiological context, KV10.1 expression pattern is limited to adult brain and 
myoblasts, and virtually absent in peripheral tissues (Occhiodoro et al., 1998). In 
myoblasts, KV10.1 contributes to the hyperpolarization required for the differentiation 
of these cells in post-mitotic, fusion-competent myotubes (Bijlenga et al., 1998). In 
brain, KV10.1 channels have preferential presynaptic localization, and contribute to 
short-term synaptic plasticity. Parallel fiber/Purkinje cell synapses of KV10.1 knockout 
mice show increased short-term facilitation (Mortensen PhD thesis, 2012). KV10.1-
deficient mice show no detectable alterations during embryogenesis and develop 
normally to adulthood. No major behavioral effects were detected, apart from a mild 
hyperactivity and longer lasting haloperidol-induced catalepsy (Ufartes et al., 2013). 
However, despite the only partially characterized role of KV10.1 in physiology, this 
channel subfamily has been extensively studied because of their involvement in 
oncogenesis (see section 1.4.2). 
 
1.4.1 Electrophysiological properties of KV10.1 
 
KV10.1 is a voltage-gated potassium channel producing slow activating, outward 
rectifying currents, which do not inactivate. A slight inward rectification is observed 
with strong depolarizations, compatible with block by intracellular sodium (Pardo et al., 
1998). The best known KV10.1 blockers are astemizole, imipramine (García-Ferreiro et 
al., 2004) and dofetilide (Ficker et al., 2001). However, none of these compounds is 
specific for KV10.1, since they also block KV11 channels. Additionally, KV10.1 is 
relatively insensitive to the commonly used potassium channel blockers 
tetraethylammonium acetate (TEA) and 4-aminopyridine (Brüggemann et al., 1993). 
KV10-elicited currents have a defining electrophysiological feature, making them easily 
distinguishable from other ion channels. This consists in a marked dependence of the 
activation kinetics on the potential prior to the stimulus: KV10.1 activates faster the 
more depolarized the potential was before the stimulus (see Fig. 4). This phenomenon is 
reminiscent of the shift described by Cole and Moore (Cole, 1978), although orders of 
magnitude more pronounced. The Cole-Moore shift is augmented by extracellular 
magnesium and protons in a dose-dependent manner (Terlau et al., 1996). KV10.1 
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channels function is inhibited by intracellular Ca
2+
/calmodulin (CaM), through the 
Ca
2+
/CaM binding domains on both N- and C- termini (Schönherr et al., 2000; Ziechner 
et al., 2006; Gonçalves and Stühmer, 2010).  
 
 
Figure 4 Cole-Moore shift effect. KV10.1 activation kinetics are strongly influenced by the pre-pulse 
potentials. Pre-pulse conditioning time interval is highlighted with a red dotted line. The black line is 
associated with the depolarization time. Figure modified from (Ludwig et al., 1994). 
 
Interestingly, another factor modulating KV10.1 channels current is the phase of the cell 
cycle: macroscopic current derived from injection of rat KV10.1 channels into Xenopus 
laevis oocytes was regulated during cell cycle, since maturation in oocytes triggered by 
mitosis-promoting factor altered the current properties. Current amplitude was reduced, 
and this effect was accompanied by a strong inward rectification (Brüggemann et al., 
1997). Currents compatible with KV10.1 profile have been detected in several cancer 
cell lines. In this context, KV10.1 current is also dependent on the cell cycle, as human 
neuroblastoma cells synchronized in G0/G1 phase show reduced amount of Eag1 
current (Meyer and Heinemann, 1998). Using a heterologous expression system, 
Camacho and co-workers report that KV10.1 current amplitude is consistently down-
regulated at the M-phase of the cell cycle. The observed electrophysiological changes 
could be due to reorganization of the cytoskeleton occurring during the G2/M transition 
(Camacho et al., 2000). 
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1.4.2 KV10.1 and cancer 
 
The discovery of a relation between cell cycle and KV10.1function made this potassium 
channel attractive for cancer research. Soon it was shown that KV10.1 channels possess 
oncogenic properties. Cell lines transfected with KV10.1 acquire features typical of 
cancerous cells, showing faster growth rate, losing cell contact inhibition, being able to 
keep growing in very low serum concentrations and inducing formation of aggressive 
tumors when injected into immune-depressed mice (Pardo et al., 1999). Expression of 
currents compatible with KV10.1 was initially described in neuroblastoma (Meyer and 
Heinemann, 1998), and breast cancer cell lines (Ouadid-Ahidouch et al., 2001). 
Subsequently, a larger screening of KV10.1 expression levels (in terms of mRNA 
transcript and protein) was performed. Here it was confirmed that KV10.1 was not (or 
only scantly) expressed in healthy non-neural tissue while it was aberrantly expressed in 
numerous cancer cell lines, and in over 70% of the tested human cancer tissues from 
diverse origin (Hemmerlein et al., 2006; Mello de Queiroz et al., 2006). Based on their 
restricted expression pattern in normal tissue, combined with their high expression in 
cancer, KV10.1 channels have been proposed as potential candidate as early cancer 
biomarker (Farias et al., 2004; Pardo and Stühmer, 2008; Rodríguez-Rasgado et al., 
2012). 
KV10.1 pharmacological blockade with astemizole and imipramine decreases tumor cell 
proliferation in vitro (Ouadid-Ahidouch et al., 2001; Gavrilova-Ruch et al., 2002) and, 
in the case of astemizole, also in vivo: in mouse models, oral doses of astemizole (far 
below the toxicity range of the compound) reduce the progression of subcutaneous 
tumors (melanoma, pancreas and mammary carcinomas) and the frequency of 
metastasis in lung carcinoma models, with a potency comparable to the maximal 
tolerable dose of cyclophosphamide, an established chemotherapeutic compound 
(Downie et al., 2008). Additional strategies, more specific than the available 
pharmacological tools, for the inhibition of the expression and/or function of KV10.1 
have also been successfully developed. Interfering-RNA against KV10.1 transcript leads 
to a reduction in proliferation in cell lines expressing this channel (Weber et al., 2006). 
Moreover, a monoclonal antibody specifically targeting the pore region of the channel 
and blocking its function, inhibits tumor cell growth both in vitro and in vivo (Gómez-
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Varela et al., 2007). Another promising approach aiming treatment of KV10.1-positive 
tumors combines the specificity of a single chain antibody targeting KV10.1 with the 
potency of TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), an 
apoptosis-inducing molecule. This fusion protein successfully induced apoptosis 
selectively to tumor cells, leaving alive the surrounding non-cancer cells (Hartung et al., 
2011). 
The contribution of KV10.1 channels to tumorigenesis is not completely dependent on 
its function as ion channel. Engineered KV10.1 channels bearing a mutation in the pore 
region that cancels ion permeation are still capable of increasing cell proliferation and 
tumor growth in immune-deficient mice, emphasizing a non-canonical function for 
these channels. Recent reports provide additional evidence for KV10.1 non-canonical 
function in cancer. Conformational changes of the voltage sensor of the channel may 
activate of p38 MAPK kinases signaling, a critical pathway modulating cell 
proliferation (Hegle et al., 2006). KV10.1 expression in mammalian cells results in 
increased secretion of VEGF (vascular endothelial growth factor), providing an 
increased vascularization to the KV10.1-positive tumor miroenvironment. Moreover, an 
increased HIF-1 (hypoxia-inducible factor 1) transcription factor activity, activating 
many genes promoting cell survival under hypoxic conditions has been detected in 
KV10.1 expressing cells (Downie et al., 2008). KV10.1 channels are also expressed at 
the inner nuclear membrane, where their amino- and carboxyl- terminal region exposed 
to the nucleoplasm could interact with heterochromatin, modulating accordingly gene 
expression (Chen et al., 2011). 
 
 
1.5 Alternative splicing 
 
pre-mRNA splicing represents a crucial step in mRNA maturation: introns are removed 
and exons are joined together, leading to a single gene product for each transcriptional 
unit in a process called constitutive splicing. Proteomes are however much more 
complex than genomes. The human genome contains 20,000—25,000 protein-coding 
genes, only four times those found in the yeast Saccharomyces cerevisiae. The genome 
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of Drosophila melanogaster contains fewer protein-coding genes (~14,000) than the 
apparently simpler organism Caenorhabditis elegans (~19,000)(International Human 
Genome Sequencing Consortium, 2005). A way to expand proteomic complexity 
without increasing the number of genes consists of generating two or more different 
proteins from a single gene by alternative splicing (AS) (Hui, 2009). The multiple 
mRNAs originated by AS from a single gene often encode structurally and functionally 
different proteins with specific enzymatic activity, ligand binding properties, cellular 
localization, protein stability and/or post-translational modifications. AS is a very 
common biological event, with up to 95% human multiexon genes exhibiting it (Barash 
et al., 2010).  
The splicing reaction is catalyzed by a set of multicomponent ribonucleoprotein 
complexes that form the spliceosome, which recognizes the intron-exon boundaries 
along the pre-mRNA and catalyzes the reactions that removes introns and joins exons. 
Exon recognition by the spliceosome machinery is achieved through the identification 
of conserved intronic dinucleotides: GU at the 5’ (donor) and AG at the 3’ (acceptor) 
ends. Constitutive splicing occurs at strong splice sites, which are always recognized by 
the spliceosome. The exact sequence around the splicing site determines the affinities of 
cognate splicing factors, eventually affecting their recognition by the splicing 
machinery (Kornblihtt et al., 2013). Weaker sites, where the pre-mRNA sequence 
diverges from the consensus can promote the occurrence of alternative splicing. 
The use of weak sites is regulated by RNA binding, trans-acting proteins (repressors 
and activators) and cis-acting regulatory sites (silencers and enhancers) on the pre-
mRNA. Exonic and intronic splicing enhancers (ESEs/ISEs) promote exon recognition, 
while exonic and intronic splicing silencers (ESSs/ISSs) reduce the probability that a 
neighbouring site is used as a splice junction (Matlin et al., 2005). The majority of 
splicing repressors are heterogeneous nuclear ribonucleoproteins (hnRNPs) and 
polypyrimidine tract binding protein (PTB). Most of the activator proteins that bind to 
ESEs are members of the SR protein family. Such proteins contain RNA recognition 
motifs and arginine and serine-rich (SR) domains. Although commonly considered as 
repressors, individual hnRNPs can also promote the usage of alternative splice sites, 
mainly through ISEs (Matlin et al., 2005). Moreover, additional RNA binding proteins  
can function as splicing regulators by binding ISSs or ISEs (Lewin et al., 2011). The 
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coordinated expression and/or activity of splicing trans-acting proteins determines the 
composition of the pool of protein isoforms in a given cell type, developmental stage 
etc. Adding further complexity to this system, the effects of regulatory factors are 
sometimes position-dependent. For example, a splicing factor can be an activator when 
bound to an intronic enhancer element, and a repressor when bound to an exon (Lim et 
al., 2011). Alternative exon usage is also modulated by secondary structure of the pre-
mRNA (Warf and Berglund, 2010), transcriptional rates of RNA polymerase II, 
chromatin structure and modifications (Kornblihtt et al., 2013).  
The relative positions of weak and strong sites may give rise to different modes of 
alternative splicing, as summarized in Fig. 5. One or more exons can be either included 
or excluded from the final transcript (exon skipping); an alternative 3’ and 5’ splice 
sites can favor the lengthening or shortening of a particular exon; a portion of an intron 
can be included in the final transcript (intron retention). Exon skipping is the most 
common mechanism of AS, accounting for ~40% of the entire alternative splicing 
events (Keren et al., 2010). 
 
 
Figure 5 Mechanisms of alternative splicing. Schematic representation of different strategies of AS. 
Grey boxes represent exons; the black lines joining them are introns. The blue lines indicate the splicing 




1.5.1 Impact of pre-mRNA splicing in disease  
 
Due to the complexity of the alternative splicing mechanism, mutation may occur at 
different levels along the splicing reaction and modify the splicing pattern. Mutations 
involving cis-acting regulatory sites along the pre-mRNA sequence can disrupt the 
normal splicing patterns or activate alternative splice patterns in an inappropriate tissue 
or developmental stage, as is the case of familial isolated growth hormone deficiency 
type II, where an increased alternative splicing of the growth hormone gene results in 
short stature (Binder et al., 1996). Mutations in components of the spliceosome or in 
their auxiliary factors cause retinitis pigmentosa (loss of rod photoreceptors)(Faustino 
and Cooper, 2003), or spinal muscular atrophy (loss of spinal cord motorneurons 
resulting in skeletal muscle denervation) (Kolb et al., 2007). Changes in alternative 
splicing patterns are also associated with neoplasia and metastasis (Philips and Cooper, 
2000), as is the case of CD44 in pancreatic ductal carcinoma (Günthert et al., 1991), 
NF1 in neurofibromatosis (Ars et al., 2000), BRCA1 and BRCA2 in ovary and breast 
cancer (Claes et al., 2003), or the oncogene MDM2 (Bartel et al., 2002). 
Manipulation of alternative splicing may open new therapeutic avenues. Isoform-
specific antisense oligonucleotides and interference RNAs have been developed and 
tested for the treatment of several diseases, ranging from certain types of thalassemia 
and dystrophies, to cystic fibrosis, cancer, and pain (Forte et al., 2005; Sazani and Kole, 
2003). Bifunctional oligonucleotides that bind specific regions of pre-mRNAs and then 
modify splicing mechanism via an antisense-targeting domain can enhance the inclusion 
of exon 7 in the SMN2 transcript and reduce the severity of spinal muscular atrophy 
(Owen et al., 2011). Additional approaches use compounds that affect phosphorylation 
of splicing factors (Pilch et al., 2001), stabilize putative pre-mRNA secondary structures 
(Varani et al., 2000), or directly interact with spliceosome components. Two natural 
compounds interfering with the spliceosome (Spliceostatin A and Pladienolide) display 






1.5.2 Impact of AS on ion channels physiology and pathophysiology 
 
Alternative splicing modulates features of several ion channels, affecting their 
physiology and pathophysiology. AS modulation may result in changes in 
electrophysiological properties, surface expression, intracellular localization and 
pharmacological profile of ion channels. For example, CaV1.2 have a cardiac-specific 
splice isoform showing less sensitivity to diltiazem, a potent vasodilator (Zhang et al., 
2010). It is also known that alternative splicing in this particular channel is regulated by 
the PTB protein (a trans-acting splicing regulator protein), mediating a switch between 
two mutually exclusive exons. Mutations in either of these two exons underly the 
Timothy syndrome (a systemic disorder, resulting in a severe pleiotropic disease 
phenotype) (Tang et al., 2011). Alternative splicing in the C-terminus of CaV1.3 
modulates its electrophysiological properties, and CaV1.4 channels express 19 splice 
isoforms, some of them with characteristic electrophysiological behavior (Tan et al., 
2011). 
A naturally occurring variant of NaV1.1 recovers more rapidly from inactivation. This is 
thought to modify the seizure likelihood and response to anti-epileptic drugs (Fletcher, 
et al., 2011). The cardiac Nav1.5 channels have at least nine splice variants, which can 
have either unchanged electrophysiological properties, altered kinetics or produce non-
functional channels. The distribution of the variants involves species-dependent, tissue-
specific, and developmental factors (Schroeter et al., 2010). 
KCa1.1 channels represent a typical example of extensive AS in potassium channels. 
These are encoded by a large gene consisting of 35 exons; here AS leads to the 
production of channels with distinct properties, including differences in calcium/voltage 
sensitivity (Chen et al., 2005), subcellular targeting (Zarei et al., 2004) and regulation 
by cellular signaling pathways (Erxleben et al., 2002; McCartney et al., 2005; Tian et 
al., 2001). Remarkably, one of the short isoforms is not functionally expressed at the 
cell surface and acts as a dominant negative of cell surface expression by trapping other 
KCa1.1 channel α-subunits in the endoplasmic reticulum and perinuclear compartments 
(Chen et al., 2005). Similarly, in a breast cancer cell line a functionally inactive variant 
of Kir3.1 exerts a dominant negative effect on the full-length channel (Wagner, 
Stadelmayer et al., 2010). The same applies in a physiological context for K2P2.1 
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channels in the brain (Veale et al., 2010) or to KCa3.1 in human lymphoid tissues (Ohya 
et al., 2011). Two spliced isoforms of KV11.1 expressed almost exclusively in tumors 
form heterotetramers with the full length channels, down-regulating the current and 
blocking cell differentiation and inducing escape from apoptotic death (Guasti, Crociani 
et al., 2008). 
 
1.5.3 KV10.1splice isoforms 
 
The human KV10.1 channel gene has eleven exons: the long N-terminal cytoplasmic 
region is encoded by exons one to five; exons six and seven encode the transmembrane 
domains, and exons eight to eleven generate the long C-terminal cytoplasmic region of 
the channel. As mentioned previously, a second KV10.1 splice variant (KV10.1b) was 
cloned in 1994, where exon 6 is spliced 81 base pairs downstream the site for the short 
variant (via alternative 5’ splicing site), forming exon 6b. KV10.1a and KV10.1b show 
the same expression pattern and similar electrophysiological features. 
Sun and colleagues (2009) reported the expression of a Drosophila KV10.1 splice 
variant, in COS cells transfected with a full length D-KV10.1 cDNA. Such protein (that 
they called Eag80) contains both N- and C-terminal sequences of the full-length channel 
but lacks all channel-forming transmembrane domains. Eag80 production is stimulated 
by either PKA or PKC, and by calcium influx. Eag80 can activate a MAPK kinase 
signaling pathway affecting the cell morphology (Sun et al., 2009). 
More recently two short isoforms derived from exon skipping events have been 
described in the human KV10.1 channel. They were named E65 and E70 after the 
predicted molecular weight of 65 and 70 kDa, respectively. E65 lacks exons from 4 to 
9, while E70 is missing exon 4 to 7 (see Fig. 6). Both E65 and E70 mRNA are devoid of 
transmembrane domains. Therefore, they do not form a functional ion channel. E65 was 
cloned from tumor cell lines (Ramos Gomes PhD thesis) and E70 from human brain 






Figure 6 Exon organization of the full-length channel transcripts KV10.1a, KV10.1b, and of the 
truncated isoforms E65 and E70. Boxes represent exon sequences, the black line connecting them are 
intron sequences. More in details, orange boxes represent exons coding N-terminal region of the channel 
protein; brown exons encode the transmembrane domain, blue exons the C-terminal region. The green 
and red lines depicted on the KV10.1 b sequence represent the splicing sites determining E65 and E70 
expression. 
 
Finally, it has been found that E65 modifies the electrophysiological properties of the 
full-length channel when both are co-expressed in Xenopus laevis oocytes. The 
modified current resembles the one recorded from mature oocytes. This is due to a 
direct activation of the maturation of the oocyte by E65, suggesting a role in cell cycle 










2. Aims of the work 
 
 
2.1 General Aim 
 
To study the impact of alternative splicing on KV10.1 biological properties 
 
2.2 Specific Aims 
 
To confirm the expression of KV10.1 short isoforms in native system 
To check for interaction between KV10.1 and its short isoforms 
To investigate the impact of E65 and E70 expression on the electrophysiological 
properties of KV10.1  




















3. Materials and Methods 
 
 
3.1 Cell cultures 
 
3.1.1 Mammalian cell lines and media composition 
 
Cell lines DU 145 (ACC 261), HEK 293 (ACC 305), HeLa (ACC 57), IPC 298 (ACC 
251), IGR 39 (ACC 239), IMR 32 (ACC 165), and SH-SY5Y (ACC 209) were 
purchased from DSMZ (Braunschweig, Germany). MDA-MB 435S (HTB 129) were 
from ATCC (Manassas, VA, USA), PNT 2 (ECACC95012613) were obtained from 
ECACC (Salisbury, UK). GL15 cells were kindly provided by Dr. Fioretti (University 
of Perugia, Italy). Each cell line was propagated and maintained according to the 
provider’s instructions: HEK 293 cells were maintained in Dulbecco's MEM/F12 1:1 
(Gibco) supplemented with 10% FCS (PAA); DU 145, PNT 2 and GL 15 in Dulbecco's 
MEM (Gibco) with 10% FCS; HeLa, IPC 298, MDA-MB 435S and SH-SY5Y in RPMI 
1640 (Gibco) with 10% FCS. IMR 32 cells were cultured in RPMI 1640 complemented 
with non-essential amino acids (Gibco) and 20% FCS; IGR 39 in Dulbecco's MEM with 
15% FCS. The culture medium of the stably transfected HEK-pTRACER-KV10.1cells 
was complemented with the antibiotic Zeocin (Invivogen) at a concentration of 3 μg/ml. 
 
3.1.2 Cell cultures: routine handling  
 
Cells were routinely grown in T25 or T75 flask (Sarstedt) and incubated in a Heracell 
240 CO2 incubator (Thermo Scientific) at 37 °C and 5% CO2. As cells reached ~90% 
confluence, the culture medium was removed, and cells were firstly washed once with 
10 ml Phosphate Buffered Saline (PBS, Gibco), then 2 ml Trypsin/EDTA solution 




, Biochrom) were added. Cells were then 
maintained for 4 min in the incubator, subsequently resuspended in 5 ml culture 
medium and placed in a sterile centrifuge tube (Greiner Bio One) and finally 
centrifuged 2 min at 1,200 x g at room temperature (RT). The supernatant was carefully 
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removed and cell pellets were thoroughly resuspended in a suitable amount of fresh 
culture medium (usually 3-5 ml), according to the desired dilution, and seeded in new 
vessels. When needed, cells were counted using a Neubauer chamber: 10 µl of cells 
resuspension were added to 30 µl Trypan Blue solution (0.4% in PBS, Sigma). 
Unstained (viable) cells in each of four large squares of the chamber were counted. The 
total number of live cells for each ml medium is represented by the number of counted 
cells multiplied by 1 x10
4
. When needed, cells were frozen according to the following 
procedure: the pellet derived from ~1 x10
6 
trypsinized cells was resuspended in 500 µl 
culture medium and added to a cryovial (Greiner Bio One) containing 500 µl of freezing 
medium (50% DMEM/F12; 25% FCS; 25% DMSO (Sigma)), which was immediately 
placed in a freezing container (Nalgene) and stored for 24 hours at -80 °C. Cells were 
then stored indefinitely in liquid nitrogen. To start a culture from frozen cells, cryovials 
were incubated 5 min at 37 °C; their content was added to a centrifuge tube containing 
10 ml of pre-warmed growth medium and centrifuged at 1,000 x g for 3 min. The 
obtained cell pellet was resuspended and placed in a new vessel. The medium was 




For all the experiments of this work two transfection modalities were employed: 
liposome-based (Lipofectamine 2000, Invitrogen) and electroporation technology 
(Nucleofector, Lonza). 80-90% confluent cells cultivated in T25 flasks were generally 
used for Lipofectamine transfections. Briefly, tube A (containing 12.5 µl Lipofectamine 
in 250 µl Opti-MEM (Gibco)) and tube B (containing 5 µg DNA in 250 µl Opti-MEM) 
were incubated 5 min at RT. Afterwards the content of A was added to tube B, followed 
by another 20 min RT incubation. In the meanwhile cells were washed in PBS and the 
growth medium was replaced with 3.5 ml Opti-MEM medium. To the cells were finally 
added 520 µl of the mixture Lipofectamine-DNA (proportion 2.5:1) in Opti-MEM and 
they were incubated for 5 hours. After this time the flask content was replaced with 4 ml 
of growth medium. Regarding electroporation-based transfections, cells at 80-90% 
confluence and grown on T25 or T75 flasks were trypsinized, washed once in PBS, 
counted and centrifuged. For each transfection 100 µl nucleofection solution (solution 
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V, proprietary composition) and 4 µg plasmidic DNA were added to 1-2 x10
6 
cells, and 
a current pulse (program A-23 for HEK cells, G-04 for SH-SY5Y cells) was applied to 
the mixture cells-DNA. Cells were finally plated at a suitable density in the chosen 
vessel. Transfection efficiency ranged between 30% and 90% depending on the cell 
type, transfection method, and sequence of plasmidic DNA. Transfected cells were used 
for further experiments 24-72 hours after transfections. 
 
3.1.4 Xenopus laevis oocyte preparations 
 
Oocytes were obtained by survival surgical laparotomy from anesthetized (tricaine 
0.2%) Xenopus laevis frogs (purchased from Nasco). They were defolliculated under 
collagenase digestion: oocytes were incubated for two hours with shaking motion at 18 
°C in a solution containing 1.4 mg/ml collagenase (SERVA) diluted in calcium-free 
Barth’s medium (88 mM NaCl; 1 mM KCl; 2.4 mM NaHCO3; 0.82 mM MgSO4; 7.5 
mM Tris-HCl, pH 7.5). The oocytes were rinsed several times with calcium-free Barth’s 
medium, then washed with Barth’s medium including calcium (Barth-medium calcium-
free complemented with 0.33 mM Ca(NO3)2, 0.41 mM CaCl2 and 0.1 mM gentamicin 
(Roth)). Oocytes were finally kept in ND96 medium (96mM NaCl; 2 mM KCl; 0.2 mM 
CaCl2; 2 mM MgCl2; 5 mM HEPES; 0.5 mM teophylline (Sigma), 0.1 mM gentamicin, 
pH 7.5) and incubated at 18 °C (Memmert incubator). Stage VI oocytes were sorted and 
used for downstream applications within 24 hours after the preparation. 50 nl cRNA 
solutions (corresponding to 0.025 – 1 ng cRNA) were injected into each oocyte using a 
Nanoject and 3.5 inches long glass pipettes (both from Drummond); after this process, 
only oocytes with homogenous pigmentation and normal turgor were collected. All the 








3.2 Molecular biology 
 
3.2.1 Total RNA isolation. 
 
Cells in culture were trypsinized and counted as previously described. Aliquots of 
≤5x10
6
 cells were centrifuged at 1,200 x g for 2 min RT; supernatant was removed and 
the pellets were washed with 5 ml PBS and centrifuged again at 1,200 x g for 2 min RT. 
Pellets derived from this process were immediately placed on ice and stored at -80°C or 
directly processed to extract total RNA. In the latter case cells were lysed with 350 µl 
RLT buffer (Qiagen) complemented with 143 mM of -mercaptoethanol (Sigma). The 
lysates were passed several times through a 25-gauge needle. To homogenize and 
eliminate insoluble debris from the lysates, these were placed in QIAshredder spin 
columns (Qiagen) and centrifuged 2 min at top speed (16,100 x g; all the centrifugations 
of this protocol were performed in a benchtop microcentrifuge at RT). Homogenized 
lysates were mixed with 1 volume of 70% ethanol in DEPC-treated water, loaded onto 
RNeasy Mini spin columns (Qiagen) and centrifuged 30s at 11,000 x g. The flow-
through was discarded and the RNA binding the silica-gel membrane of the column was 
washed with 350 µl of RW1 buffer and centrifuged 30s at 11,000 x g. RNA samples 
were then treated with RNase free DNase (Qiagen) in order to eliminate genomic DNA. 
For each sample a solution containing 20 µl (54 Kunitz units) of DNase and 140 µl 
RDD buffer (supplied with the RNase-Free DNase Set) was prepared. 160 µl of this 
solution were pipetted into the columns and incubated 30 min RT. Then 350 µl of RW1 
were added and, after further 5 min incubation, the samples were centrifuged 30s at 
11,000 x g. Then, 500 µl RPE buffer were added to the columns and centrifuged 30s at 
11,000 x g; a second wash with 500 µl RPE buffer was followed by 6 min 
centrifugation at top speed in order to dry the columns. These were incubated with 30 µl 
DEPC-treated water for 6 min at RT and finally centrifuged again 6 min at top speed in 
order to elute RNA. The RNA amount and quality were assessed by spectrophotometric 
measurements (Nanophotometer, Implen): only RNA samples having A260/A280 and 




3.2.2 mRNA isolation 
 
For isolation of mRNA, the Micro-FastTrack 2.0 Kit (Invitrogen) was used. Up to 500 
μg of total RNA per sample were precipitated adding 1/10 vol sodium acetate 5 M and 
2.5 vol ice-cold Ethanol 100%. The samples were stored 60 min at -20 °C, then 
centrifuged 15 min at 4 °C top speed (16,100 x g). RNA pellets were washed once with 
70% ethanol, and resuspended in 10 µl Elution Buffer (10 mM Tris-HCl, pH 7.5 in 
DEPC-treated water). The solution was added to 1 ml Binding Buffer (500 mM NaCl, 
10 mM Tris-HCl, pH 7.5 in DEPC-treated water), heated up to 65 °C for 5 min and 
placed immediately on ice for 1 min. The solution containing RNA was pipetted onto a 
vial of oligo(dT) cellulose. The tube was tightly sealed, allowing the oligo(dT) cellulose 
to swell for 2 min. After that, it was incubated under rocking at room temperature for 20 
min. The oligo(dT) cellulose was then centrifuged at 4,000 × g in a microcentrifuge for 
5 min at RT. The supernatant was carefully removed from the resin bed. The oligo(dT) 
cellulose was resuspended in 1.3 ml Binding Buffer (500 mM NaCl, 10 mM Tris-HCl, 
pH 7.5 in DEPC-H2O) and centrifuged again at 4,000 × g for 5 min at RT. This washing 
step was repeated four more times, until the buffer appeared no longer cloudy. The resin 
was subsequently resuspended in 300 µl Binding Buffer, transferred to a spin column 
and centrifuged at 4,000 × g for 30s at RT. The latter resuspension/centrifugation step 
was repeated four more times. The resin was finally resuspended in 200 μl Low Salt 
Wash Buffer (250 mM NaCl, 10 mM Tris-HCl, pH 7.5 in DEPC-treated water) and 
centrifuged at 4,000 × g for 30s at RT. This last step was repeated once. The spin 
column was then placed into a new RNase-free microcentrifuge tube and 100 μl Elution 
Buffer (10 mM Tris-HCl, pH 7.5 in DEPC-treated water) was mixed into the cellulose 
bed and centrifuged at 4,000 × g for 30s at RT. A second aliquot of 100 μl Elution 
Buffer was added to the column, mixed into the cellulose, and centrifuged again 30s at 
RT. In order to collect any remaining eluate, a centrifugation at 4,000 × g for 1 min at 
RT was performed. The eluted mRNA was precipitated with 10 μl of 2 mg/ml glycogen 
carrier, 30 μl of 2 M sodium acetate, and 600 μl of 100% ethanol. The samples were 
placed on dry ice for 20 min, then centrifuged at maximum speed for 15 min at 4 °C. 
The supernatant was carefully removed and discarded. The pellet was washed with 70% 
ethanol. The ethanol was removed, and the pellet was air-dried for 5–10 min. the 
mRNA pellet was finally resuspended in 10 μl Elution Buffer (10 mM Tris-HCl, pH 7.5 
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in DEPC-treated water). mRNA amount and purity were assessed by means of 
spectrophotometric measurements.  
 
3.2.3 Capped RNA (cRNA) synthesis 
 
This was obtained performing in vitro transcription using the T7 mMessage mMachine 
Kit (Ambion). pSGEM vector containing the gene of interest was linearized with SfiI 
(as described in 3.2.6.1). The digestion was terminated by adding 1/20 vol 0.5 M 
EDTA, 1/10 vol 3 M sodium acetate and 2 vol of 100% ethanol. The samples were 
mixed thoroughly and chilled at –20 °C for one hour. DNA was then precipitated at 
16,100 x g for 15 min at 4 °C. The supernatant was removed, the tubes were re-
centrifuged for a few seconds, and the residual supernatant was disposed. Pellets were 
air-dried for 7 min and resuspended in a volume of TE buffer adequate to obtain a final 
DNA concentration of 0.5–1 μg/μl. The reaction of in vitro transcription was assembled 
at RT, adding the following components in a sterile microcentrifuge tube: DEPC-water 
(to 20 μl final volume), 10 μl 2X NTP/CAP, 2 μl 10X Reaction Buffer, 1 μg linear 
template DNA, 2 μl T7 Enzyme Mix. The samples were incubated for 2 hours at 37 °C. 
cRNA was then recovered by lithium chloride precipitation: 30 μl DEPC-H2O and 30 μl 
LiCl Precipitation Solution (7.5 M lithium chloride, 50 mM EDTA) were added to the 
samples, mixed thoroughly and chilled for one hour at –20 °C. The tubes were 
microcentrifuged at 16,100 x g for 20 min at 4 °C to pellet the RNA and the supernatant 
was carefully removed. RNA pellets were washed with ~500 μl 70% ethanol, RNA 
pellet were air-dried for 7 min before being resuspended in ~30 μl DEPC-H2O. After 
determined the RNA concentration and purity, the samples were frozen at –80 °C. 
 
3.2.4 cDNA synthesis 
 
SuperScript First-Strand Synthesis system (Invitrogen) was used for cDNA production. 
5 µg total RNA were added to 0.5 µg OligodT12-18mer and DEPC-water, till 12 µl total 
volume. The mixture was incubated 10 min at 70 °C, then placed for 1 min on ice. After 
that, 7 µl of reaction buffer composed by RT Buffer (57 mM Tris-HCl, 143 mM KCl, 
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pH 8.4), 7 mM MgCl2, 29 mM DTT (DL-Dithiothreitol; Clelands reagent), 1.4 mM 
dNTP mix were added to the tubes, which were incubated 5 min at 42 °C. Afterwards, 
200 U SuperScript II reverse transcriptase was added to each sample, and 1 µl of 
DEPC-treated water was used in the –RT control samples. All the samples were then 
incubated 50 min at 42 °C, followed by 15 min at 70 °C. 2 U RNase H were also used 
for each tube, which were incubated for 20 min at 37 °C. 29 µl of DEPC-water were 
added, in order to obtain 50 µl cDNA having concentration of 0.1 µg/µl. 
 
3.2.5 Polymerase Chain Reaction (PCR) 
 
PCR reactions were performed using 10 ng template plasmidic DNA (or 100 ng first 
strand cDNA), 2.5 µl 10X reaction buffer (containing 20 mM Tris-HCl, 10 mM 
(NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1% Triton X-100, pH 8.8; from New 
England Biolabs), 200 µM dNTP mix (New England Biolabs), 0.2 µM of each specific 
primers (synthesized by Sigma), 1.2 U of Taq DNA polymerase (New England Biolabs) 
and sterile H2O, up to 25 µl final volume. The thermocycler (Mastercycler, Eppendorf) 
was set up using the following amplification program: 20 cycles of amplification 
including, after an initial denaturation step of 3 min at 95 °C, 95 °C for 30s, 59 °C (or 
different temperature, depending on the Tm of the primers) for 30s, 72 °C for 3 min. 
Nested PCR reactions were performed using 150 ng first strand cDNA, 2.5 µl 10X 
reaction buffer (containing 20 mM Tris-HCl, 10 mM (NH4)2SO4, 10 mM KCl, 2 mM 
MgSO4, 0.1% Triton X-100, pH 8.8), 200 µM dNTP mix, 0.2 µM of each specific 
primers, 1.2 U of Taq DNA polymerase and sterile H2O, up to 25 µl final volume. The 
thermocycler settings were as follows: 20 cycles of amplification including, after an 
initial denaturation step of 3 min at 95 °C, 95 °C for 30s, 59 °C for 2 min and 30s, 72 
°C for 3 min. After this, 1 µl of the product of this reaction was used as template for the 
second round PCR. The reaction consisted now of 35 cycles: after an initial 
denaturation step of 3 min at 95 °C, 95 °C for 30s, 59 °C for 2 min and 30s, 72 °C for 2 
min). The amplification products were loaded on a 1.2% agarose gel containing 5 µl 
(for each 100 ml gel volume) Serva DNA stain G (SERVA). Electrophoresis was 
performed at 100 V for ~40 min; the electrophoretic mobility was visualized with UV 




Table 1 List of the primers used for PCR and nested PCR amplification. 
 
Real-time PCR experiments were also performed. For this purpose a LightCycler 480 
(Roche) thermocycler and the TaqMan probes system were used. Each PCR reaction 
consisted of 200 ng first strand cDNA sample, 5 µl hot-start-PCR-mix (containing 
FastStart Taq DNA polymerase, reaction buffer, MgCl2 and dNTP mix, from Roche), 
0.5 U Uracil-DNA-glycosylase (New England Biolabs), 1 µl primer mix (containing 
900 nM forward and reverse primers, plus 250 nM TaqMan probe) and DEPC-water, up 
to 10 µl final volume. The oligonucleotides used are listed in table 2. PCR amplification 
protocol was set as follows: initial denaturation steps (2 min at 50 °C and 10 min at 95 
°C) were followed by 50 cycles made by 10s at 95 °C; 15s at 56 °C; 1 min at 60 °C. The 
program ended at 40 °C for 30s. The resulting amplification data for each target gene 
were standardized to the amount of the housekeeping gene, the human transferrin 










Primer name Sequence (5’-3’) 
E70 Forward ATT GAA AAA GTG CGG CAA AC 
E70 Reverse GGC ACC TGG TAG AGC TTC AG 
KV10.1 External Forward TGT TCG GCG GTC CAA TGA TAC TAA 
KV10.1 External Reverse TCC CGG CCC CCT CTC TCA 
KV10.1 Internal Forward TTG GGG AAT GCT CAG ATA GTG G  
KV10.1 Internal  Reverse GGC CTC ATT CTT TCG TTT CAT 
30 
 
























TGA CTG ATA AAG ACA 















Table 2 List of the TaqMan probes and primers used for real-time PCR. The human transferrin 
receptor was used to control for RNA integrity. 
 
3.2.6 Cloning  
 
DNA derived from nested PCR experiment possess A-overhanging ends which, after 
purification, can be easily cloned into pGEM-T vector (Promega), having T-
overhanging ends and provided in linearized state by the manufacturer. In the other 
cases the cloning procedure implies digestion using one or more restriction enzymes 
(NEB) and purification of the products before performing the ligation. 
3.2.6.1 Restriction enzyme digestion 
 
All the digestions were performed using restriction enzymes and reaction buffers 
provided by New England Biolabs. 8 µg DNA from vector and insert plasmids were 
digested with 1-2 µl restriction enzyme(s), together with the appropriate buffer. The 
following component were added to a sterile tube placed on ice: 8 µg DNA template to 
digest, 1-2 µl enzyme(s), 3 µl buffer; dH2O up to a final volume of 30 µl. Time and 
temperature of incubation were depending on the type of enzymes used. 
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3.2.6.2 Dephosphorylation  
 
It was necessary to perform dephosphorylation in order to avoid recircularization of the 
plasmid if the enzymes would generate compatible ends after digestion. For this, the 
tubes were heated to 65 °C for 20 min in order to inactivate the enzymes after the 
digestion; subsequently 3.45 µl of 10X Antartic Phosphatase Buffer and 1 µl Antartic 
phosphatase enzyme (New England Biolabs) were added. Finally the tubes were 
incubated 20 min at 37 °C (60 min if the restriction enzyme leaved 3’ extensions) and 
heat-inactivated 5 min at 70 °C. All the digestion products were run on a 0.8% agarose 
gel containing Serva DNA stain G for ~40 min at 100 V, excised using a clean scalpel 
under UV light, and collected in a sterile tube for the purification. 
3.2.6.3 DNA purification 
 
The fragment of agarose gel containing the amplified DNA of interest or the digested 
DNA was weighted, and either stored at +4 °C or processed immediately for DNA 
purification. For this purpose, the NucleoSpin Extract II kit (Macherey Nagel) was 
employed. To start, 200 µl of NTI binding buffer provided with the kit was added for 
each 100 mg gel containing the DNA. The mixture was incubated 10 min at 50 °C and 
vortexed at intervals of two minutes in order to facilitate the agarose melting. The 
content of the tube was pipetted into a NucleoSpin column and centrifuged 30s at 
11,000 x g (all the centrifugations of this protocol were performed at RT). 
Subsequently, 700 µl of buffer NT3 were added to the column and centrifuged again; 
this washing/centrifugation step was repeated one more time before performing a final 
centrifugation 3 min at 16,100 x g in order to dry the silica membrane. The NucleoSpin 
column was then placed in a sterile microcentrifuge tube. Depending on the expected 
amount of DNA recovered, 20-30 µl NE buffer (5 mM Tris-HCl, pH 8.5) were added to 
the silica membrane; the columns were incubated for 3 min and afterwards centrifuged 
3 min at 16,100 x g to elute DNA. The quality and amount of the purified DNA were 
estimated loading 1 µl of the eluted in a 1% agarose gel and performing densitometry 
analysis: after electrophoretic run performed for ~40 min at 100 V, gel was exposed 
under UV illumination and, using the software Quantity One (Bio-Rad), the amount of 
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signal derived from the purified DNA was compared to the one from DNA band at 3 kb 
(containing 125 ng DNA) of the 1 kb ladder (New England Biolabs). 
3.2.6.4 Ligation 
 
A mass ratio 1/3 between vector DNA and insert DNA was generally used for ligation. 
The enzyme used was T4 ligase (New England Biolabs). As an example, in a sterile 
microcentrifuge tube were added 1 μl of 10X T4 DNA Ligase buffer (50 mM Tris-HCl, 
10 mM MgCl2, 10 mM Dithiothreitol, 1 mM ATP, pH 7.5), 0.05 pmol pGEM-T vector 
DNA having 3 kb length, 0.15 pmol of a purified DNA fragment 1 kb long and 
autoclaved water, reaching 10 μl final volume. The reaction was carried out incubating 
samples at 16 °C overnight. 
3.2.6.5 Transformation 
 
Competent DH5α E. coli (Life technology) were thawed on ice and 5 μl DNA from 
ligation samples was added to them. Cells were incubated on ice for 30 min, heat-
shocked for exactly 45s at 42 °C, then placed back on ice for additional 2 min. After 
this, 200 μl LB medium (Luria Bertani broth: 1% Peptone 140; 0.5% Yeast extract; 1% 
NaCl; from Invitrogen) were added to the tubes, which were subsequently incubated at 
300 rpm at 37 °C for one hour. The transformed bacteria were spread on pre-warmed 
LB-agar plates containing ampicillin (100 μg/ml) or kanamycin (50 μg/ml) and 
eventually containing X-Gal 20 mg/ml and IPTG 100 mM for the blue/white selection 
of the colonies. The plates were incubated overnight at 37 °C.  
 
3.2.7 Small scale plasmid DNA preparation (Mini-prep) 
 
NucleoSpin Plasmid QuickPure kit (Macherey Nagel) was used in order to isolate small 
scale plasmid DNA from transformed competent bacteria. A single transformed colony 
was added to a tube containing 5 ml LB medium complemented with ampicillin (100 
μg/ml) or kanamycin (50 μg/ml) and incubated overnight in an orbital shaker at 200 rpm 
37 °C. The tube was then centrifuged at 5,000 x g for 10 min at 4 °C. The supernatant 
was discarded and the pellet was resuspended in 250 μl resuspension buffer provided 
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with the kit (A1) and transferred to a microcentrifuge tube. Subsequently 250 μl buffer 
lysis buffer (A2) were added and the content of the tube was gently mixed by inverting 
it 8 times. After 5 min incubation RT, 300 μl neutralization buffer (A3) were further 
added, the tube was inverted again 8 times and then centrifuged at 11,000 x g for 5 min 
at RT. The supernatant was placed in a NucleoSpin Plasmid QuickPure column 
previously mounted on a collection tube and centrifuged for 1 min at 11,000 x g RT. 
The flow-through was discarded and 450 μl wash buffer (AQ) were added; a centrifuge 
of 3 min at 11,000 x g RT was performed in order to wash and dry the column, which 
was then placed on top of a sterile microcentrifuge tube. 30 μl elution buffer (AE, 5 mM 
Tris-HCl, pH 8.5) were added, and then finally the tube was incubated for 2 min at RT 
and centrifuged at 11,000 x g for 2 min at RT. Amount and purity of the eluted DNA 
was assessed by spectrophotometric analysis. 
 
3.2.8 Endotoxin-free plasmid DNA preparation  
 
Endotoxin-free plasmidic DNA for transfection of mammalian cells was obtained using 
NucleoBond Xtra Midi EF kit (Macherey Nagel). A single transformed colony was 
added to a tube containing 5 ml LB medium complemented with ampicillin (100 μg/ml) 
or kanamicin (50 μg/ml) and incubated 6-8 hours in an orbital shaker at 200 rpm 37 °C. 
This starter culture was subsequently diluted in a flask containing 100 ml LB medium 
complemented with the appropriate antibiotic and incubated overnight in an orbital 
shaker at 220 rpm 37 °C. Each culture was subdivided in 2 x 50 ml tubes, which were 
centrifuged at 5,000 x g for 10 min at 4 °C. Pellets were resuspended in 8 ml 
resuspension buffer (RES-EF), lysed by adding 8 ml lysis buffer (LYS-EF) and gently 
mixed by inverting the tubes six times. The mixture was incubated for 5 min at RT; in 
the meanwhile a filter was inserted into a NucleoBond Xtra column aiming to avoid to 
clog the column with insoluble cell debris. The columns was equilibrated using 15 ml 
equilibration buffer EQU-EF. After the 5 min incubation, 8 ml neutralization buffer 
(NEU-EF) was applied to the suspension, the tubes were gently mixed by inverting 12 
times and incubated 5 min on ice before loading the whole content into the equilibrated 
NucleoBond Xtra Column Filter. The first wash was performed using 5 ml washing 
buffer (FIL-EF), the filter was then carefully removed from the column, which was now 
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washed first with 35 ml washing buffer (ENDO-EF) and afterwards with 15 ml washing 
buffer (WASH-EF). The column was allowed to empty by gravity flow and then loaded 
with 5 ml elution buffer (ELU-EF): the plasmidic DNA was eluted in a sterile 15 ml 
tube, precipitated using 3.5 ml isopropanol and centrifuged at 15,000 x g for 30 min at 4 
°C. The supernatant was carefully discarded and pellet was washed with 2 ml 70% 
ethanol and centrifuged at 15,000 x g for 5 min at 4 °C. The ethanol was carefully 
removed from the tube and the DNA was dried for 10 min at RT before being 
reconstituted using a suitable amount of TE-EF buffer (100-300 μl, depending on the 
pellet size, in order to obtain a final DNA concentration of 2 μg/μl). Amount and purity 
of the eluted DNA were assessed by spectrophotometric analysis. 
 
3.2.9 Site-directed mutagenesis 
 
In order to obtain the desired point mutation (leucine was replaced with tyrosine in the 
TCC of KV10.1 channels), the QuikChange II XL Site-Directed Mutagenesis Kit 
(Agilent technologies) was used. The plasmidic DNA to be mutated was first diluted to 
a concentration of 5 ng/μl. The reaction assembled in a sterile microcentrifuge tube 
placed on ice consisted of 10 ng plasmidic DNA, 125 ng of each primer L20Y F (5’-
AGGAGGACATCAAGGCCTACAACGCCAAAATGACCAATA-3’) and L20Y R 
(5’-TATTGGTCATTTTGGCGTTGTAGGCCTTGATGTCCTCCT-3’), 2.5 μl 10X 
reaction buffer, 1.5 μl QuikSolution reagent (to improve amplification efficiency), 1 μl 
(200 µM) dNTP mix, 15.9 μl dH2O and finally 1.25 U Pfu Ultra HF DNA polymerase. 
The samples were thermocycled according to the following settings: initial denaturation 
step of 1 min at 95 °C, 18 cycles of amplification at 95 °C for 50s,, 60 °C for 50s, 68 °C 
for 8 min 30s and a final extension step at 68 °C for 7 min. 3 μl of the amplified sample 
were loaded on a 0.8% agarose gel to check whether the amplification was successful. 
The remaining amplified DNA was incubated 60 min at 37 °C with 10 U of the 
restriction enzyme DpnI which digested the parental (methylated) dsDNA. 3 μl of the 
digested DNA were used to transform an aliquot of DH5α cells, as described in 
paragraph 3.2.6.5. In order to confirm the success of the mutagenesis, the resulting 




3.2.10 Probe preparation for RNase protection assays and in vitro transcription 
 
The ~200 bp region spanning the area between exon 3 and exon 8 of KV10.1 was used 
as E70 probe (Fig. 7). This sequence was amplified by PCR using pcDNA3-E70Venus 
as DNA template and the E70 specific primers listed in table 1. The amplified E70 
probe DNA was then cloned into pGEM-T and linearized using the restriction enzyme 
SacI HF overnight at 37 °C. These procedures are described in paragraphs 3.2.6 and 
3.2.6.1. Linearized DNA was precipitated and purified as follows: 10 μl 0.5 M EDTA, 
20 μl 5M ammonium acetate and 130 μl ethanol were added to a sterile tube, mixed 
thoroughly, and chilled one hour at -20 °C. Samples were then centrifuged at 16,100 x g 
for 15 min at 4 °C. DNA pellet was washed in 70% ethanol, centrifuged at 16,100 x g 
for 2 min at 4 °C. Pellet was allowed to air-dry 10 min and finally resuspended with 10 
μl sterile, nuclease-free H2O. 
The reaction of in vitro transcription was carried out using the MAXIscript kit 
(Ambion). In parallel with the E70 probe, in each experiment a sample containing 
mouse actin sequence (validated probe provided by the kit supplier) was also used, as 
well as RNA ladder (from Ambion) to estimate the size of the probes. The in vitro 
transcription reaction was assembled at RT in sterile microcentrifuge tubes, consisting 
of 1 μg template DNA (or 0.5 μg RNA ladder), 2 μl 10X transcription buffer; 500 μM 
each of ATP, CTP and GTP solutions; 50 μCi α-[
32
P] UTP (15 μCi α-[
32
P] UTP for 
RNA ladder), providing a final concentration of ~3.125 μM radiolabeled-UTP (~0.94 
μM for RNA ladder). 30 U T7 Enzyme Mix and nuclease-free water to 20 μl were 
finally added. The components were mixed and, after a brief centrifugation, incubated 
for one hour at 37 °C.  
In order to digest the remaining DNA eventually present in the tubes, 2 U TURBO 
DNase (included in the kit) were added to the reactions, followed by incubation 15 min 
at 37 °C. 1 μl of 0.5 M EDTA solution was then added to stop the reaction. 0.5 μl 
solution were taken from each tube and the amount of radiolabel incorporated was 
measured at a scintillation counter (Beckman LS 6000). One million counts-per-minute 
(cpm) was the threshold value indicating a satisfactory [
32
P]UTP incorporation. 









Figure 7 Nucleotide sequence of the RNA antisense probe targeting E70 transcripts. The antisense 
RNA sequence length is 292 nt, while the E70 probe length is 197 nt). 1-51: T7 promoter start region and 
multi cloning site; 52-175: exon 8 antisense part; 176-248: exon 3 antisense part; 249-292: final part of 
the probe, ending with SacI-HF restriction site. 
 
Before proceeding with ribonuclease protection assay, the freshly produced RNA 
probes were gel purified in order to exclude prematurely terminated transcription 
products, as well as unincorporated nucleotides. For this purpose, a denaturing 5% 
polyacrylamide gel was prepared. In a sterile vial were added 7.2 g urea, 1.5 ml 10X 
TBE solution, 1.9 ml 40% Acrylamide and dH2O to 15 ml final volume. The mixture 
was stirred at RT to completely dissolved the urea, then 120 μl 10% ammonium 
persulfate and 16 μl TEMED were added, and immediately the gel was poured in a 
suitable gel cassette. After the polymerization (usually 30 min) the gel was placed into 
an electrophoresis cell filled with TBE buffer. At the end of gel preparation, 15 μl gel 
loading buffer II (95% Formamide, 0.025% xylene cyanol, 0.025% bromophenol blue, 
18 mM EDTA, 0.025% SDS) were added to the samples (5 μl of loading buffer to 5 μl 
the RNA ladder aliquot), heated for 3 min at 95 °C, briefly centrifuged and finally 
loaded and run at 150 V for ~45 min. After this time, the gel was extracted from the 
cassette, covered with transparent plastic wrap, pasted into a X-ray cassette and exposed 
for 30s to a X-ray film (Fujifilm). The film was finally developed using a Curix 60 
device (Agfa healthcare). The expected full-length probe sizes were 304 nucleotides (nt) 
for pTRI-Actin-Mouse and 292 nt for pGEM-T E70 probe (Fig. 8 A). The areas of the 
gel containing full-length transcripts were excised with a scalpel, transferred to a 
RNase-free microfuge tube, submerged in 350 μl of Probe Elution buffer (500 mM 
ammonium acetate/1 mM EDTA/ 0.2% SDS) and incubated overnight at 37 °C. 
Another X-ray film was exposed to the gel to ensure that the whole amount of full-




Figure 8 Gel purification of RNA probes for RNase protection assay. X-ray plate before (A) and after 
(B) excision of the full-length RNA probes. 
 
Purification from unincorporated radionucleotides was performed also in RNA ladder 
samples, using IllustraMicroSpin G-50 columns (GE Healthcare). Briefly, the columns 
were prepared for the experiment as suggested by the manufacturer, subsequently 15 μl 
of the freshly synthesized ladder were applied to the column placed upon a fresh sterile 
microcentrifuge tube. Purified RNA ladder was eluted by centrifugation at 735 x g for 2 
min at RT. The amount of radioactive label of the eluted RNA antisense probes and 
RNA ladder was assessed by scintillation counting of 1 μl of each solution. The 
detected values were in the range between 50,000-100,000 cpm/μl for the probes and 
about 250,000-300,000 cpm/μl for the RNA ladder. 
 
3.2.11 RNase Protection Assay (RPA) 
 
RPA experiments were performed using the RPA III kit (Ambion). Each experiment 
was carried out including both positive and negative controls provided by the 
manufacturer, constituted respectively by an actin probe-hybridizing mouse liver RNA 
and yeast RNA, to eventually reveal any unspecific background signal. 
To start the experiment, 3 µg mRNA (equivalent to and 200,000 cpm purified RNA 
antisense probes were placed in sterile, RNase-free microcentrifuge tubes. 1/10 vol of 5 
M ammonium acetate and 2.5 vol of ethanol were subsequently added; tubes were 
mixed thoroughly and stored at –20 °C for one hour, allowing RNA to precipitate. The 
samples were then centrifuged at 16,100 x g for 20 min at 4 °C. The supernatant was 
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discarded and RNA pellets were washed with 70% ethanol, briefly centrifuged and air-
dried for ~5 min.  
Each pellet was resuspended in 10 μl hybridization III buffer provided with the kit, 
heated for 4 min at 93 °C to denaturate RNA, and then incubated overnight at 42 °C to 
allow probes to hybridize. 
Unprotected RNA was digested after incubation using enzyme mix RNase A/RNase T1 
Mix diluted 1/100 in RNase digestion III buffer; 150 μl of this solution were added to 
each sample. Additionally, 150 μl of digestion III buffer were added to the no-RNase 
control tube(s), as a control for probe integrity. The RNA digestion was performed for 
30 min at 37 °C, and was followed by addition of 230 μl RNase 
Inactivation/Precipitation III solution.  
The samples were mixed thoroughly, chilled at –20 °C for one hour and centrifuged at 
16,100 x g for 20 min at 4 °C. In the meantime a 5% polyacrylamide gel was prepared, 
as described in paragraph 3.2.10. After centrifugation the supernatant was removed and 
RNA pellets were washed with 70% ethanol, briefly centrifuged and air-dried for ~5 
min. RNA pellets were resuspended in 10 μl gel loading buffer II (95% Formamide, 
0.025% xylene cyanol, 0.025% bromophenol blue, 18 mM EDTA, 0.025% SDS), 
vigorously vortexed and heated for 4 min at 93 °C before being loaded into the gel. The 
amount of RNA ladder loaded was 40,000 cpm (corresponding to ~1.5 μl of a 1/10 
diluition of a 300,000 cpm/μl column-purified solution), complemented with 5 μl gel 
Loading Buffer II. Only 20% of the No-RNase tube content was loaded, since a higher 
radioactivity level is expected compared to the other samples. Electrophoretic 
separation was carried out at 150 V for ~45 min. After this time, the gel was placed on 
Whatman paper, wrapped into a plastic foil, pasted into a X-ray cassette and exposed to 
a X-ray film at -80 °C for a time ranging between overnight to four days, depending on 
the amount of hybridized probe on target RNA. The film was finally developed using a 
Curix 60 device (Agfa). The expected sizes of the protected probes were 245 nt for 







3.3.1 Western blotting (WB) 
 
3.3.1.1 Cells lysis for SDS-PAGE 
 
80-90% confluent cells cultivated in T75 flasks were washed twice in PBS, scraped off 
the flasks using 3 ml PBS, and centrifuged at 800 x g for 3 min at RT. Pellets were 
resuspended in 400 µl ice-cold lysis buffer (50 mM Tris-HCl pH 7.4; 300 mM NaCl; 5 
mM EDTA; 1% Triton X-100; a tablet of cOmplete protease inhibitor (PI) cocktail 
(Roche) was used for each 10 ml solution) and passed several times through a 25-gauge 
needle, incubated 20 min on ice and finally centrifuged at top speed for 20 min at 4 °C. 
The supernatant was carefully removed, placed in fresh tubes and either stored at -20 °C 
or directly used for downstream application. 
3.3.1.2 Oocyte lysis for SDS-PAGE 
 
For each experimental group, fifteen Xenopus laevis oocytes were resuspended in 300 
μl (20 μl each cell) oocyte lysis buffer (150 mM NaCl, 20 mM Tris-HCl, 5 mM MgCl2, 
5 mM EDTA, 1% Triton X-100; a PI cocktail tablet was used for each 10 ml solution) 
and incubated 15 min on ice. Lysates were then centrifuged at 11,000 x g for 5 min at 4 
°C. The supernatant was carefully removed with a fine tip and placed in a fresh 
microcentrifuge tube. Samples were again incubated 15 min on ice and centrifuged at 
11,000 x g for 5 min at 4 °C. The supernatant was carefully removed, placed in fresh 
tubes and either stored at -20 °C or directly used for downstream application. 
3.3.1.3 Cells lysis for protein analysis under native conditions 
 
80-90% confluent cells cultured in T25 flasks were washed twice in PBS, scraped off 
the flasks using in 1 ml PBS solution containing PI cocktail and 200 ng/µl PefaBlock 
solution (a serine protease inhibitor, from Sigma), and transferred to microcentrifuge 
tubes. The samples were centrifuged at 1,500 x g for 3 min at 4 °C. After supernatant 
was removed, the pellet was resuspended in 800 µl ice-cold hypotonic buffer (10 mM 
Tris-HCl, 2 mM EDTA, PI and 200 ng/µl PefaBlock in H2O), passed through a 26-
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gauge needle ten times and incubated 20 min on ice. The homogenate was subsequently 
centrifuged at 400 x g for 10 min at 4 °C, to precipitate nuclei. Supernatant was placed 
in a ultracentrifuge tubes and centrifuged at 50,000 x g for 30 min at 4 °C in a TL-100 
ultracentrifuge equipped with a rotor TLA 100.3 (Beckman Coulter). Supernatant was 
carefully removed and pellet were either frozen at -80 °C, or directly processed for the 
native PAGE analysis. 
3.3.1.4 Protein quantitation 
 
Protein amount was quantified using the Pierce BCA protein assay kit (Thermo 
Scientific), 7 µl of each sample derived from the previous procedure were added to 28 
µl autoclaved H2O and 10 µl of this mixture were loaded in triplicates on a 96 well 
plate, together with triplicates of 10 µl diluted BSA (bovine serum albumin) standard, 





















30 from sample B 
0,75 
E 35 
35 from sample C 
0,50 
F 35 
35 from sample E 
0,25 
G 30 
30 from sample F 
0,125 
H 32 










Reagent B (4% cupric sulfate) was diluted 1/50 in Reagent A (sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1 M sodium hydroxide) 
and mixed thoroughly. 200 µl of this mixture was added to each sample in the 96-well 
plate, which was then incubated 30 min at 37 °C. The absorbance of the samples at 562 
nm was measured using a Wallac VICTOR
2
 plate reader (Perkin Elmer). With these 
data we could draw a titration curve, which allowed us to estimate the protein amount 
relative to our samples. 
3.3.1.5 SDS-PAGE and protein blotting on nitrocellulose membrane 
 
NuPAGE Tris-Acetate SDS Buffer Kit (Invitrogen) was used for all SDS-PAGE 
experiments. Running buffer was prepared diluting 50 ml of 20X Tris-acetate Running 
buffer (containing 1 M Tricine, 1 M Tris Base, 70 mM SDS in H2O, pH 8.25) in one 
liter distilled water; from this, 200 ml were placed into another vessel and 
complemented with 500 μl Antioxidant (containing N,N-Dimethylformamide and 
sodium bisulfate). A Pre-cast gel NuPAGE Novex 3–8 % Tris-acetate (Invitrogen) was 
loaded into a XCell SureLock electrophoresis cell (Invitrogen). 200 ml of freshly 
prepared buffer containing antioxidant were poured in the inner part of the chamber, 
with the running buffer placed the outer part. A maximal volume of 45 μl sample was 
loaded per well, along with 10 μl of pre-stained ladder (New England Biolabs), and 
electrophoresis was performed at 150 V for one hour. In the meantime, 1.2 liters of 
transfer buffer were prepared, consisting of 10 mM NaHCO3, 3 mM Na2CO3, 20% 
methanol and 0.01% SDS solutions at pH 9.22. After the electrophoretic separation, 
proteins were transferred from gel to a nitrocellulose membrane (Amersham Hybond 
ECL - GE Healthcare) using a tank transfer method: both membrane and gel were 
incubated in transfer buffer and shaked for 10 min. The ‘sandwich’ for the transfer 
consisted on the gel containing the protein placed in tight contact with the membrane, 
surrounded by two pieces of Whatman paper and a sponge for each side of the 
sandwich. This complex was placed into the transfer tank Mini Trans-Blot Cell (Bio-
Rad) within a gel holder cassette (Bio-Rad). The transfer protocol consisted of a voltage 
gradient from 10 to 40 V, increased by steps of 10 V every 10 min, and followed by a 
final step of 40 min at 50 V. The nitrocellulose membrane was removed from the 
sandwich and air-dried overnight at RT. 
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3.3.1.6 Blue Native PAGE (BN-PAGE) and protein blotting on PVDF membrane 
 
BN-PAGE is a sensitive and high resolution tool for analysis of the molecular mass and 
oligomeric state of proteins in native conformation (Schägger and von Jagow, 1991). 
All the components (detergent, running buffers, protein ladder) used in BN-PAGE 
experiments were purchased from Invitrogen. Frozen pellets derived from cell lysates 
(procedure described in paragraph 3.3.1.3) were thawed on ice and resuspended in 200 
µl sample buffer (50 mM BisTris-propane, 750 mM 6-aminocaproic acid, pH 7 
complemented with PI/10 ml solution). The protein concentration was measured as 
described in paragraph 3.3.1.4. In fresh microcentrifuge tubes, 250 ng of protein lysate 
were mixed with 12 µl (6% final concentration) n-Dodecyl β-D-Maltopyranoside 
(DDM, a mild detergent) and diluted with sample buffer in order to achieve 14 µl final 
volume. The mixture was incubated for 60 min on ice. After that, 6 µl (1.5% final 
concentration) Coomassie G 250 were added and the samples were centrifuged at 
16,100 x g for 10 min at 4 °C. Anionic dye Coomassie blue G 250 binds the negative 
charges of the amino acids, replacing SDS as charge-shift molecule, and maintaining in 
this case the protein structures in their native state. During the time of incubation with 
the detergent, a Native PAGE Novex 3-12% Bis-Tris pre-cast gel was loaded into a 
XCell SureLock electrophoresis cell, which was then filled in the outer part with 
NativePAGE Running Buffer (50 ml NativePAGE Running Buffer 20X containing 950 
ml dH2O) and internally with Dark Blue buffer (10 ml Cathode Additive, 10 ml 
Running Buffer, 180 ml dH2O; final G-250 amount 0.02%). The wells were loaded with 
10 µl of sample supernatant and 7 µl NativeMark protein ladder (Life technologies). 
Electrophoretic separation lasted for one hour at 150 V at 4 °C; after this time, the Dark 
Blue buffer was replaced with Light Blue buffer (1 ml Cathode Additive, 10 ml 
Running Buffer, 189 ml dH2O; final G-250 amount 0.002%) and the samples were 
allowed to run for additional 3 hours at 250 V. After that, the proteins were transferred 
onto a PVDF membrane (Amersham Hybond-P; GE healthcare) using the Trans-Blot 
SD Semi-Dry Transfer Cell (Bio-Rad). Three Whatman paper pieces were placed on the 
transfer apparatus: the first pre-soaked in Buffer I (300 mM Tris-HCl, pH 10.4 and 10% 
methanol), and two pre-soaked in Buffer II (25 mM Tris-HCl, pH 10.4 and 10% 
methanol). The PVDF membrane (previously incubated in methanol for 1 min, then 3 
min in dH2O, finally in Buffer II immediately before loading), and the gel were then 
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added. Finally the last 3 pieces of Whatman pre-soaked in Buffer III (25 mM Tris-HCl 
pH 10.4; 40 mM aminocaprionic acid; 20% methanol) were applied on top of the gel. 
The transfer time was 30 min at 2.5 mA/cm
2
 of membrane. After blotting, the 
membrane was incubated in 8% acetic acid for 15 min and air-dried overnight at RT. 
The lane containing the unstained ladder was separated from the other samples, 
incubated 10 min in methanol, washed 5 times with dH2O and incubated 30 min with 
Ponceau S (Merck Millipore) solution 0.1% in 1% acetic acid. The excess of staining 
was removed by several washes in dH2O, until the ladder bands could be detected and 
promptly marked on the PVDF membrane containing the samples lanes. 
3.3.1.7 Two-dimensional Blue Native PAGE (2D BN-PAGE) 
 
The macromolecular composition of KV10.1 complexes derived from BN-PAGE 
experiments was investigated using a SDS-PAGE approach as second dimension 
following a BN-PAGE (Schägger et al., 1993). The sample preparation and the BN-
PAGE procedures were carried out as described in paragraph 3.3.1.3 and 3.3.1.6. After 
the electrophoresis, the lane containing the sample of interest was excised from the 
native gel with a scalpel and incubated in equilibrating solution (ES; made of 1% SDS 
in 0.125 mM Tris-HCl, pH 7.0) for 20 min, then in ES complemented with 100 mM 
Dithiothritol (DTT) for 25 min. After that, gel was incubated in ES with 60 mM 
Iodoacetamide for 25 min and finally pure ES for 10 min. The equilibrated lane was 
placed in the 2D well of a NuPAGE Novex-Tris Acetate 3-8 % SDS gel. 10 µl of 
prestained protein marker (Bio-Rad) were loaded in the ladder lane. The SDS-PAGE 
and protein blotting on nitrocellulose membrane were performed as described in 3.3.1.5. 
3.3.1.8 Membrane blocking and protein signal detection 
 
The dried nitrocellulose membrane was incubated in dH2O (or in methanol for PVDF 
membranes, followed by 3x dH2O washes) for 15 min. The Pierce Western Blot Signal 
(Thermo Scientific) Enhancer was used: solution A was applied to the membrane for 2 
min then 5x washed with dH2O. Then the solution B was added, incubated for 10 min 
and finally washed again 5x with dH2O. To block unspecific binding sites of the 
antibody, the blotted membrane was incubated for 1 hour with 0.1% Casein (Roche) in 
TBS-T (TBS containing 0.1% Tween 20) solution. After that, a primary antibody 
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diluted in 0.1% casein TBS-T (see table 4) was applied for 90 min, followed by 7x 
washes with deionized H2O and 5 min incubation in TBS-T. Subsequently the 
membrane was incubated for one hour with secondary ECL anti-rabbit (or anti-mouse, 
depending on the primary antibody species) IgG antibody horseradish peroxidase 
(HRP)-linked (GE Healthcare), diluted 1/7000 in 0.1% casein TBS-T. The membrane 
was washed again seven times with deionized H2O and incubated in TBS-T for 5 min. 
For the detection of the protein signal, the membrane was incubated for 5 min with 
Immobilon Western Chemiluminescent HRP Substrate (Millipore) and luminescence 
was imaged using a Chemi-Doc XRS system (Bio-Rad). 
 
3.3.2 Immunoprecipitation (IP) 
 
An amount of 100 to 500 µg protein lysates (isolated and quantified as described in 
3.3.1.1 and 3.3.1.4), together with respectively 15 to 25 μl of Protein G magnetic beads 
(New England Biolabs) was first incubated for 1 hour at 4 °C in order to pre-clear the 
crude cell extract, excluding from the experiment non-specific binding to the beads. A 
magnetic field was applied to the mixture for 30s and the beads were trapped in one side 
of the tube. The supernatant was then placed in a fresh tube, where 2 μg of a 
monoclonal antibody (see table 4) were also added. The tube content was mixed and 
incubated for one hour or ON (depending on the antibody) at 4 °C. 25 μl of magnetic 
beads were added to the suspension, vortexed and incubated for one hour at 4 °C. The 
beads were recovered in a magnetic field, washed 3 times with 400 μl protease-free 
wash solution (0.1% Triton X-100, 50 mM Tris-HCl, 300 mM NaCl, 5 mM EDTA, 
complemented with PI tablet for each 10 ml solution). Finally, an additional wash with 
400 μl protease-free TBS (TRIS buffered saline: 50 mM TRIS, 150 mM NaCl, pH 7.6) 
was performed. The beads were resuspended in 16.25 μl TBS, 2.5 μl 10X Sample 
Reducing Agent (500 mM DTT, from Invitrogen) and 6.25 μl of 4X LDS sample buffer 
(40% glycerol, 6.8% Tris-Base, 6.6% Tris-HCl, 8% LDS, 0.06% EDTA, 0.75% Serva 
Blue G250, 0.25% Phenol Red, from Invitrogen), till reaching a final volume of 25 μl. 
For each sample, a no-IP (input) tube, containing 10% of the immunoprecipitated 
amount of protein, together with 1/4 vol LDS and 1/10 vol SRA was also prepared. All 
the samples were incubated for 10 min at 70 °C and then exposed to a magnetic field to 
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separate beads from supernatant. The IP supernatant, input and a protein ladder (New 














2 μg (IP); 
2 μg/ml 
(ELISA) 
Ip, ELISA L.A. Pardo; 
(Hemmerlein 





0.5 μg each IP L.A. Pardo; 
(Hemmerlein 
et al., 2006). 
1218 Monoclonal, 
mouse 
GFP (used for 
mVenus) 
2 μg IP Abcam 
6556 Polyclonal, 
mouse 
GFP (used for 
mVenus) 





1/1500 WB L.A. Pardo; 
(Napp et al., 
2005). 
 
Table 4 List of primary antibodies used in IP, ELISA and WB. 
 
3.3.3 Glycosidase digestion 
 
200 µg of protein lysate were immunoprecipitated, as described in 3.3.2. After the 
overnight antibody incubation and the addition of protein G magnetic beads, the 
magnetic beads were resuspended in 2 μl Beads Release solution (100 mM β-
mercaptoethanol in 0.1% SDS), in order to release the proteins complexes bound to the 
beads. Samples were heated up to 99 °C for 10 min, briefly centrifuged, and exposed to 
a magnetic field in order to trap the beads at one side of the tube. At this point, the 21 μl 
supernatant from each sample were distributed in three microcentrifuge tubes, for 
treatment with Endo H, PNGase F (both from Sigma), and a control tube (CTL), 






 EndoH sample PNGase F sample CTL sample 
100 µg protein lysate 7 μl 7 μl 7 μl 
dH2O 9,5 μl 
Diluted with its own 
buffer 
18 μl 
Buffer 5 μl 12 μl - 
Denaturing solution 2,5 μl 2,5 μl - 
Samples denaturated at 100 °C for 5 min, then placed on ice 1 min and finally treated with: 
Detergent solution - 2,5 μl - 
Enzyme 1 μl 1 μl - 
 
Table 5 Endo H and PNGase F digestions: list, and used amount of the components for each 
sample. 
 
The tubes were incubated ON at 37 °C and then mixed with SRA and LDS buffers for 
SDS-PAGE, as described in paragraph 3.3.1.5. 
 
3.3.4 KV10.1 -BBS system for quantification of surface KV10.1 
 
3.3.4.1 Sample preparation 
 
Insertion of a BBS at the extracellular part of KV10.1 allows specific labeling of 
membranous KV10.1-BBS in intact cells (Kohl et al., 2011). HEK-KV10.1-BBS cells 
cultured on T75 flasks were washed once with 10 ml PBS. For each flask, 4 ml PBS 
containing α-Bungarotoxin (BTX)-Biotin (Invitrogen) at final concentration of 2.5 
µg/ml were added, followed by incubation on ice for 10 min. The α-BTX-Biotin 
solution was removed and the flasks were washed twice with ice-cold PBS. Cells were 
scraped in 4 ml ice-cold PBS, centrifuged at 800 x g for 3 min. Cell pellets were 
resuspended with 400 µl lysis buffer (20 mM Tris-HCl, 150 mM NaCl, 5 mM MgCl2, 
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1% Nonidet- P40, pH 7.4, containing a PI tablet each 10 ml solution). The lysates were 
passed several times through a 25-gauge needle and placed in microcentrifuge tubes, 
incubated for 20 min on ice and finally centrifuged at 16,100 x g for 15 min at 4 °C. 
Supernatants were placed in fresh tubes and the protein concentration was quantified as 
described in paragraph 3.3.1.4. 
3.3.4.2 Enzyme-Linked ImmunoSorbent Assay (ELISA) 
 
The entire procedure was performed on ice. 96-well streptavidin-coated plates (Thermo 
Scientific) were washed twice with PBS containing 0.05% Tween 20, 0.1% BSA and 
0.1% Triton X-100. Each sample was placed in six wells of the 96-well plate (triplicates 
of 30 and 150 µg of protein) and incubated 30 min. The plates were washed twice and 
then incubated for 30 min with 100 µl NPE (150 mM NaCl, 5 mM EDTA, 50 mM Tris, 
5mM KCl, 1% NP-40; pH 7.5) blocking solution containing 1% casein to remove 
unspecific binding sites of the antibody. 50 µl for each well of primary antibody anti-
KV10.1 diluted in NPE with 0.1% casein (final antibody concentration 2.5 µg/ml) were 
then added to the wells and incubated 90 min. The samples were washed 3 times with 
100 µl NPE buffer containing 0.1% casein and incubated again with 100 µl NPE 
blocking solution (with 1% casein) for 30 min. At this point, 50 µl/well of secondary 
ECL HRP-linked anti-mouse IgG (GE Healthcare) (diluted 1/500 in NPE with 0.1% 
casein) were added to the wells and the mixture was incubated 90 min. After this, each 
well was washed 7 times with 100 µl NPE buffer containing 0.1% casein. Finally, 200 
µl substrate 3-ethylbenzothiazoline-6-sulphonic acid (ABTS, from Invitrogen) were 
added for each well. The chromogenic peroxidase reaction was measured using a plate 
reader at 405 nm with a reference wavelength of 490 nm. 
 
3.3.5 Cell fixation for fluorescent proteins imaging 
 
Confluent CHO cells (~80-90%) were plated on poly-L-lysine coated 25 mm coverslips 
in 6-well plates and transfected as described in paragraph 3.1.3. About 24 hours after 
transfection, the medium was removed and wells were washed twice with 2 ml PBS. 
Cells were fixed in formalin solution (Sigma) for 10 min at 4 °C, then washed twice (5 
min each) in PBS. Permeabilization of the membrane was performed incubating cells in 
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PBS with 0.5% Triton X-100 (Sigma) for 5 min RT. Samples were afterwards washed 
twice (5 min each) with PBS-T (PBS with 0.1% Tween-20 (Merck-Millipore)). 
ProLong Gold antifade reagent (Invitrogen) containing the membrane-impermeable 
nuclear staining DAPI was finally used to mount the coverslips on microscope slides 
Superfrost Plus (Thermo scientific). Mounted coverslips were air-dried for at least one 





3.4.1 Two-electrode voltage clamp 
 
Voltage clamp recordings of cRNA-injected Xenopus laevis oocytes (Stühmer, 1998) 
were performed 24-48 hours after injection, using a Turbo TEC-10CD amplifier (npi 
Electronics). Currents derived from cRNA-injected oocytes and DEPC-H2O injected 
oocytes (negative control) were all recorded at RT. The intracellular electrodes having a 
resistance of 0.7-1.5 MΩ were filled with 2 M KCl. The external solution (Normal Frog 
Ringer, NFR) contained 115 mM NaCl, 2.5 mM KCl, 1.8 mM, CaCl2, 10 mM Hepes, 
pH 7.2. Data were acquired with PULSE software (HEKA Electronics) and analyzed 
with IgorPro (Wavemetrics). For all protocols, the currents were filtered at 2 kHz and 
then sampled at a frequency of 10 kHz. The membrane potential was held at -80 mV. In 
order to characterize current-voltage relationships, an I-V protocol was used, generally 
consisting of 250 ms voltage pulses, ranging from +80 mV to -60 mV, with 20 mV 
decrements. To compare voltage-elicited current response between different groups of 
oocytes, the average steady state current from 80 to 95% time of the pulse was plotted 
against the voltage. As mentioned in section 1.4.1, the activation kinetics deceleration 
under hyperpolarized holding potentials is a hallmark of the KV 10.1 channel (Terlau et 
al., 1996). This was determined using the following protocol: +40 mV pulses were 
applied for 500 ms after hyperpolarizing conditioning pulses (5000 ms) at -120 mV and 
-60 mV. The rise time of activation was established as the time required from 20% to 
80% of the maximal current. 
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3.4.2 Whole cell patch clamp electrophysiology 
 
HEK-KV10.1 cells were transfected (as described in paragraph 3.1.3) and plated in 24-
well plates, (~20,000 cells/ well) each containing a 12-mm coverslips coated with poly-
L-lysine. Recordings were performed 24-72 hours after transfections. Only cells 
showing green signal (due to the transfection of the fluorescent protein mVenus) under 
epifluorescence illumination passing through a suitable dichromatic beamsplitter 
(Excitation BP 450-490 nm; Emission LP 515 nm) were analyzed. Macroscopic KV10.1 
currents were recorded in the whole-cell configuration of the patch-clamp technique 
(Hamill et al., 1981), using an EPC-9 amplifier and Patchmaster software (both from 
HEKA). Patch pipettes were pulled (with a List-Medical vertical puller) from WPI - 
PG10165-4 glass (World precision Instruments): the pipette resistance ranged between 
2.5 and 3.5 MΩ. The intracellular solution contained 100 mM KCl, 1 mM MgCl2, 5 mM 
BAPTA, 5 mM EGTA, 45 mM NMDG (N-methyl-D-glucamine), 10 mM HEPES; pH 
7.4, osmolarity ~290 mOsm. Extracellular solution was made of 2.5 mM KCl, 160 mM 
NaCl, 2 mM CaCl2, 1 mM MgCl2, 8 mM Glucose, 10mM HEPES, pH 7.4, osmolarity 
~300 mOsm. For all the experiments, the membrane potential was held at -80 mV. Fast 
capacity (Cfast), slow capacity (Cslow) and series resistance (RS) compensations (at 70-90 
%) were also applied. Signals were filtered at 4 kHz and sampled at 20 kHz. I-V 
protocol consisted of 250 ms (or 500 ms) voltage pulses, ranging from +80 mV to -60 
mV, with 20 mV decrements. To compare voltage-elicited current response between 
different groups of cells, the current was first normalized to the cell size (as measured 
by Cslow). The resulting current density was averaged from 80 to 90% time of each pulse 
and plotted against the voltage. A high potassium-content extracellular solution was 
also used (60 mM KCl, 102.5 mM NaCl, 2 mM CaCl2, 1 mM MgCl2, 8 mM Glucose, 
10 mM HEPES, pH 7.4, osmolarity ~320 mOsm) in order to check the voltage 
dependence of the conductance (G versus V), using a tail current protocol: each of 500 
ms voltage pulses (ranging from +80 mV to -80 mV, with 20 mV decrements) was 
followed by 300 ms hyperpolarization at -120 mV. The exponential current-decay after 
the peak tail was fitted, and the extrapolated amplitude at time zero (i.e. at the beginning 
of hyperpolarization pulse) was considered as peak tail current. G/Gmax values were 
obtained by normalizing the extrapolated peak tail current against +80 mV tail currents, 
and plotted versus voltage. Conductance–voltage curves were then fitted with a 
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Boltzmann sigmoidal function to describe the voltage dependence of KV10.1 activation, 
according to Equation 1: 
Equation 1:    G=
    
   
            
 
Where Gmax is the maximal conductance, Vhalf  represents the voltage for half-maximal 
activation, and k is the slope factor. 
 
3.4.3 Outside-out patch clamp recordings for noise analysis  
 
Non-stationary noise analysis was carried out in the outside-out configuration on 
macropatches of Xenopus oocytes (Heinemann and Conti, 1992). Briefly, 24-72 hours 
after cRNA injections, the oocyte to be analyzed was immersed ~5 min in skinning 
solution (200 mM L-Aspartic acid, 20 mM KCl, 1 mM MgCl2, 5 mM EGTA, 10 mM 
HEPES, pH 7.4), which provided the osmotic pressure to facilitate the removal of the 
vitelline membrane. This operation was performed under a strong illumination using a 
pair of fine tip forceps. The oocyte was then placed in a recording chamber containing 
NFR (external measuring solution), and allowed to attach to the bottom for 10-15 min 
before measurement. All the experiments were performed at RT, with oocytes from at 
least two different animals. Pulled patch pipettes (WPI - PG10165-4 glasses), having 
resistance 0.9 - 2 MΩ were filled with intracellular solution containing 100 mM KCl, 10 
mM EGTA, 10 mM HEPES, pH 7.2. EPC9 amplifier and Patchmaster software were 
used for the measurements. Patches were held at a holding potential of -80 mV. Signals 
were filtered at 4 kHz and sampled at 20 kHz. After establishing the outside-out 
configuration, fast capacity was compensated. Non-stationary noise analysis data were 
acquired by applying short (50 ms) depolarization pulses to +40 mV for several hundred 
times. Variance was calculated with PulseTools software (HEKA). Number of channels 
N, and single channel currents i were determined from the variance σ
2 
versus current 
amplitude I plot using the following equation 2: 
 











 represents the baseline variance. The total current I flowing through an ion 
channel results from the combination of three parameters: the unitary current through a 
single channel i, the total number of available channels N, and the probability of a 
channel being open Po (Equation 3). 
 





3.5.1 Epifluorescence microscopy 
 
In order to estimate the cell transfection efficiency, fluorescence derived from 
transfected fluorophores was visualized with a Zeiss Axiovert 200M equipped with a 
Hg-arc lamp (HBO 100 W, Osram) using an appropriate dichromatic beamsplitter filter 
set:  
 Excitation band pass (BP) 450-490; emission BP 515-565 nm for mVenus 
transfected cells, and  
 Excitation BP 546/12; emission long pass (LP) 590 nm for mCherry transfected 
cells. 
 
3.5.2 Confocal microscopy 
 
Confocal images (from samples prepared as described in paragraph 3.3.5) were acquired 
with a Leica TCS SP2 system; the scan head is mounted on a Leica DMIRE2 inverted 
microscope. Images were taken using a 63X oil immersion objective having numerical 
aperture 1.4. The scanned stacks had ~0.3 μm thickness. Laser line and filter range to 
detect the emission of each fluorophore were: DAPI (Laser line 405 nm, emission 418-
477 nm); mVenus (laser line 514 nm; emission, 526-585 nm) and mCherry (laser line 
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594 nm; emission 607-655 nm). Acquired image stacks were converted to TIFF files 
and imported into Fiji (Fiji Is Just ImageJ) software (Schindelin et al., 2012). 
Quantitative colocalization analysis were performed with the plugin JACoP (Just 
Another Colocalization Plugin) (Bolte and Cordelières, 2006), based on Pearson’s 
correlation coefficient (Adler and Parmryd, 2010). 
 
3.5.3 Live imaging 
 
IncuCyte Zoom (Essen BioScience) device was used for monitoring cell growth. After 
transfections (described in 3.1.3), the cells were plated on a suitable vessel at a 
confluence of 30-40%. The cells were loaded in the Incucyte Zoom placed into a cell 
incubator at 37 °C and 5% CO2. Under these conditions, 16 images/well (using a 10X 
objective, Nikon) were acquired at intervals of 60 min, until confluence reached 100% 
(or for a maximal time of 100 hours after transfections). The growth curve was obtained 
using the IncuCyte ZOOM 2013A software (Essen BioScience): a confluency mask was 




3.6 Flow cytometry 
 
To estimate the fraction of cells retained in different cell cycle phases, a kit based on 
DNA intercalating agent Propidium iodide (Pi) was used, the CycleTEST plus DNA 
from BD Biosciences. 48 hours post-transfections cells were trypsinized, centrifuged at 
800 x g for 3 min at RT and counted. The pellets from ~1 x10
6
 cells were washed once 
in PBS, and centrifuged again at 800 x g for 3 min at RT. The samples were resupended 
in 250 µl solution A (containing trypsin in a spermine tetrahydrochloride detergent 
buffer, to lysate the cell membranes and cytoskeletons), mixed and incubated for 10 min 
at RT. After that, 200 µl solution B (containing trypsin inhibitor and ribonuclease A, to 
inhibit the trypsin activity and to digest the RNA) were added, mixed and incubated for 
10 min at RT. Finally 200 µl solution C cold (containing Pi, staining the DNA) were 
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applied to the samples, which were mixed and incubated 10’ on ice in dark conditions. 
The samples were analyzed in a FACSAria flow cytometer (BD Biosciences) using an 
Ar 488 nm laser for excitation. The fluorescence emission was collected using 585/42 
BP filters. Linear forward and side scatter gates were used to discriminate single cells 
from cell clumps and debris. After gating, a minimum of 1 x10
4
 events was recorded for 
each sample. FACS Diva software v5.0 (BD Biosciences) was used for data acquisition. 
The resulting fluorescence histograms were analyzed with FlowJo v7.5.5 software (Tree 






Statistical analysis was performed using the software Prism (GraphPad) and Igor 
(Wavemetrics). Sample values and current amplitudes were compared by two-tailed 
unpaired Student’s t test. Pvalues below 0.05 were considered statistically significant. 
Asterisks in the figures indicate p-values (*p ≤0.05; ** p ≤0.01; ***p ≤0.005). Unless 


















splice isoforms expression in diverse cell lines 
 
Recent findings in our laboratory revealed the existence of two KV10.1 truncated 
isoforms in the human brain and in the melanoma cancer cell lines IGR 39 and IPC 298. 
These splice variants have been termed E65 and E70, based on their predicted 
molecular weight. Both the isoforms are derived from exon skipping events and are 
devoid of the whole transmembrane domains, therefore predictably non-channel 
proteins, lacking respectively exons four to nine and four to seven compared to the full-
length KV10.1 sequence (Ramos Gomes, 2010). In order to provide a more intuitive 
distinction between KV10.1 full-length channel and its short isoforms in terms of 





, respectively, based on their exon composition. 
Here, nested PCR experiments were carried out in order to consolidate previous 




 in a panel of 
KV10.1-positive cell lines. Since KV10.1 (full-length and KV10.1
Δ4−7
) is also expressed 
in brain under physiological conditions, human brain samples were also tested for short 
isoforms expression. For each nested PCR experiment, two sets of specific primers 
amplifying KV10.1 (external and internal primers, whose sequences described in table 1 
of materials and methods section) were used. The external primers anneal respectively 
to the boundary between exon 1 and 2 (forward), and exon 11 (reverse) of KV10.1 
sequence. The internal primers are located at exon 2 (forward) and exon 11 (reverse). 
Since all these primers target regions contained in both KV10.1 and its short isoforms 




expression from the 
full-length based on the differences in amplicon length. 
PCR products were separated on agarose gel electrophoresis. A band compatible with 
KV10.1, having electrophoretic mobility corresponding at about 1.9 kb, was present in 
all the tested cell lines. Additionally in certain samples amplified DNA having sizes of 








– compatible bands. 
Electrophoresis of DNA samples amplified with nested PCR. KV10.1 was visualized in all the samples. 
Additional amplified products having length of ~500 and ~900 bp appeared in IGR 39, SH-SY5Y and 
IMR 32 cells. The ~900 bp fragment was also detected in total human brain. Blank sample contains H2O 
instead of template cDNA. 
 
Positive bands were excised from the gel, DNA was purified and cloned into pGEM-T 
for sequencing using vector-specific primers. Sequencing was carried out using the 
Sanger method, with a forward primer annealing to the T7 promoter region (5’-
TGTAAAACGACGGCCAGT-3’) and a reverse primer for the SP6 promoter region 
(5’-AACAGCTATGACCATGATTACG-3’). Sequence analysis of the amplified 
fragments revealed that the shortest was a 488 bp fragment in which the end of exon 3 
was joined with the beginning exon 10 of KV10.l, thus representing KV10.1
Δ4−9
. The 
second additional amplicon was 933 bp long and represented the KV10.1
Δ4−7
 isoform, 
where the end of exon 3 was joined with the beginning exon 8 of KV10.l. The results of 
all the nested PCR experiments are summarized in table 6: KV10.1
Δ4−9
 expression was 
observed in prostate cancer cells DU 145, but also in normal prostate epithelium cells 
PNT 2. Moreover KV10.1
Δ4−9
 was detected in melanoma cancer cells IGR 39 and IPC 
298, and neuroblastoma SH-SY5Y cells. KV10.1
Δ4−7
 was detected in the neuroblastoma 















DU 145 ++ + - 
IGR 39 +++ + - 
IPC 298 ++ + - 
PNT 2 ++ + - 
SH-SY5Y +++ + + 
Human brain ++ - + 
IMR 32 +++ - + 
GL 15 + - - 
HEK-Kv10.1  ++++ - - 
HeLa +++ - - 
MDA-MB 435S ++ - - 
MCF  7 ++ - - 
 
Table 6 Summary of the results from nested PCR experiments followed by sequencing analysis. 
KV10.1
Δ4−9
 expression has been found in DU 145, IGR 39, IPC 298, PNT 2 and SH-SY5Y cells. 
KV10.1
Δ4−7
 was detected in SH-SY5Y, human total brain and IMR 32 cells. 
 





which would not be feasible with nested PCR, TaqMan probes and primers for real-time 
PCR were designed and tested. With this system we could successfully amplify both 




 sequences embedded in 
plasmidic DNA, with a detection limit of ~0.1 femtograms (Fig. 10). These primers had 









TaqMan probes amplification efficiency. Real-time PCR with 
increasing dilutions plasmidic DNA. Both KV10.1
Δ4−7
 (squares) and KV10.1
Δ4−9
 (triangles) are 
successfully amplified starting from 0.1 femtograms DNA template. Cp (Crossing point) represents the 
cycle number where fluorescence emitted from the probe increases above the threshold. 
 
Once the system was validated, real-time PCR experiments were performed using cell 




 expression in the previous nested PCR 
experiments. Unfortunately, the resulting amplification rate of both splice isoforms was 
poor (Cp ≥ 35) in all the cell lines and brain extract samples tested (data not shown), 









 in nested PCR could be explained by the fact 
that real-time PCR is less sensitive (Guo et al., 2002). 
In general, the methodology of PCR amplification is very sensitive, but on the other 
hand is also prone to give artifacts (Cocquet et al., 2006). For this reason, to 
unequivocally prove the existence of KV10.1 short isoforms in native expression 




mRNA presence in a PCR-
free system. Therefore, ribonuclease protection assays were performed. mRNAs 
isolated from diverse KV10.1-positive cancer cell lines were hybridized with 




transcripts (large amounts of human brain RNA necessary for RPA could not be 
obtained for obvious ethic issues). Single-stranded, unprotected mRNAs were digested 
and the result of the digestion was separated on a polyacrylamide gel. A 342 nt band, 
corresponding to length of the KV10.1
Δ4−9 





 was detected in IMR 32 and SH-SY5Y cell extracts (Fig. 11). Findings 





transcripts in native expression systems, as previous results 









detected with RNase protection assay. Left panel: 
KV10.1
Δ4−9 
transcript was detected in IGR 39 cell line. The protected probe size is 342 nt and undigested 
probe size 437 nt (experiment performed by Dr. Fernanda Ramos Gomes). Right panel: KV10.1
Δ4−7
 
transcript expressed in IMR 32 and SH-SY5Y cells. The protected probe size is 197 nt (undigested size 








 interaction with full-length KV10.1 channel 
 
In a wide range of ion channels, splice variants may interact with the full-length 
channel, modulating its function (see for example Chiu, et al., 2010; Veale et al., 2010; 





would interact with KV10.1 and we addressed this experimental question in a 
heterologous expression system, and with the use of biochemical and microscopy tools. 
First, co-immunoprecipitation (co-IP) experiments were performed. For this purpose, 





constructs tagged with the fluorescent protein mVenus 
(Ramos Gomes, PhD thesis 2010). The use of such a fusion protein allowed us to 
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, since an 





mVenus using an anti-GFP antibody was followed by 
blotting the membrane with an antibody against KV10.1 (targeting C-terminus region of 
the channel and recognizing also the short isoforms epitopes). Anti-KV10.1 immunoblot 
of GFP-immunoprecipitated extracts expressing KV10.1 alone did not give rise to 
detectable bands. In contrast, in IP of extracts co-expressing KV10.1
Δ4−9
 with full-length 
channel, signals compatible with KV10.1 protein (~130 kDa) were detected. The same 
was true for extracts of cells expressing full-length together with KV10.1
Δ4−7
, albeit 
quantitative and qualitative differences were present. First, the yield of full-length co-IP 
was much higher for KV10.1
Δ4−9
 than for KV10.1
Δ4−7
. Second, the bands compatible 
with KV10.1 were also qualitatively different: KV10.1
Δ4−9 
coprecipitated a diffuse band 
similar to the majoritarian form present in the inputs, while KV10.1
Δ4−7
 pulled down two 
sharper bands of smaller size, indicative of non-mature forms of the channel (see Fig. 
12 A, right panel). Input (not immunoprecipitated) samples were also used. Here, the 
~75 kDa signal corresponding to the KV10.1
Δ4−9
-mVenus protein was less intense than 
the ~85 kDa one derived from the KV10.1
Δ4−7
-mVenus protein. This is probably due to a 
less efficient transfection rate for the DNA coding for KV10.1
Δ4−9
 compared with the 
DNA coding for KV10.1
Δ4−7
. Moreover, a band having size compatible with KV10.1
Δ4−7
 
was detected in the KV10.1 + KV10.1
Δ4−9
 sample: this is probably unspecific, since it 
also appears in the KV10.1 sample (Fig. 12 A, left panel). 
In vitro interaction between KV10.1 and its short isoforms was confirmed by reverse co-
IP using a monoclonal anti-KV10.1 antibody directed against the pore region (that 
therefore does not bind to any of the shorter variants) and developing the immunoblot 
















Co-IP experiments: (A) Right panel: 
immunoprecipitation of mVenus co-precipitated KV10.1 protein of ~130 kDa in KV10.1 + KV10.1
Δ4−9 
samples and KV10.1 protein of ~110 kDa in KV10.1 + KV10.1
Δ4−7
. Left panel: input samples consisting of 
10% (20 µg) not immunoprecipitated cell extracts. (B) Immunoprecipitation of KV10.1 with a 











, confocal microscopy analyses were performed to check the 
existence (and eventually quantify the amount) of colocalization. For this purpose, CHO 
cells co-transfected with fluorescently tagged KV10.1 and short isoforms (KV10.1-
mCherry and KV10.1
Δ4−9
 -mVenus) were used. Images of formalin-fixed cells were 
acquired using a laser scanning confocal microscope (Fig. 13 A). The same experiments 
were carried out on cells co-transfected KV10.1-mCherry and KV10.1
Δ4−7
-mVenus (Fig. 
13 B). A plot profile of the two channels intensities drawn along the images already 
suggested the presence of a spatial overlap between the two fluorescent labels (Fig. 13 
C and D). More precisely, the degree of colocalization between mVenus and mCherry 
channels was quantified using the Pearson’s correlation, a statistical approach 
describing the correlation of the intensity distribution between channels: values between 
0.5 and 1 are indicative of significant correlation (Adler and Parmryd, 2010). In our 
experiments values of 0.73 ±0.09 were measured regarding interaction KV10.1
Δ4−9
-
KV10.1, while an average coefficient of 0.80 ±0.08 was obtained for KV10.1
Δ4−7
-








 colocalize with KV10.1. Confocal microscopy experiments: (A) 
Images of KV10.1
Δ4−9
-mVenus and KV10.1-mCherry and the merge of the two channels. (B) Images of 
KV10.1
Δ4−7
-mVenus, KV10.1-mCherry and the merge of the two channels. (C) Plot profile of KV10.1
Δ4−9
 
and KV10.1 channels derived from the yellow cursor in panel A. (D) Plot profile of KV10.1
Δ4−7
 and 
KV10.1 channels derived from the yellow cursor in panel B. 
 
 




 on KV10.1 electrophysiological properties 
in the Xenopus laevis expression system 
 




are interaction partners of full-
length KV10.1 channels, the next experimental task was to assess whether the short 
isoforms would affect the electrophysiological properties of the channel. In order to test 
this, Xenopus laevis oocytes were injected with RNA coding for KV10.1, or a mixture of 




, at ratio 1:1 or 1:10 
(Fig. 14 A). The macroscopic KV10.1 current was measured using the two-electrode 
voltage clamp (TEVC) technique, using a protocol where the voltage was driven from -
62 
 
60 mV to +80 mV, with voltage steps of 20 mV. In these experiments KV10.1 current 





 splice isoforms (Fig. 14 B). At 80 mV the average current reduction 
was 43.8 ±8.4% (p<0.001) and 36.1 ±9.5% (p=0.005), respectively. The KV10.1 current 





(1:10 ratio samples): 67.8 ±8.3% (p<0.001) and 65.5 ±7.4% (p<0.001) (Fig. 14 C), 
respectively. It is important to note that the current reduction detected in the cells under 




was not caused by the increased 
cRNA concentration or overloading of protein translation system since oocytes injected 
with higher quantity of KV10.1 cRNA (up to 10 ng/μl), showed considerable increase in 














Two-electrode voltage clamp recordings: (A) KV10.1 macroscopic current 
traces recorded in KV10.1, KV10.1 with KV10.1
Δ4−9
 or with KV10.1
Δ4−7
 samples at 1:1 and 1:10 ratios. (B) 
I-V graph representing the macroscopic KV10.1 current at each voltage step. (C) Bar graph resuming the 
macroscopic KV10.1 current values at +80 mV. 
 
A defining electrophysiological feature of KV10.1 channel consists in a progressive 
deceleration of activation kinetics at increasing hyperpolarizing pre-pulses, reminiscent 
of Cole-Moore shift (Ludwig et al., 1994). To estimate the influence of splice isoforms 
on KV10.1 activation kinetics, a depolarization pulse after conditioning at two different 
negative holding potentials was applied, and the rise time of activation from 20% to 
80% of maximal current was calculated for both -60 mV and -120 mV pre-pulses 
potentials for all the samples. All the recordings of cells expressing KV10.1 channels, 




splice isoforms, showed 
strong dependence of activation kinetics on pre-pulse potentials (Fig. 15 A). In 





in 1:1 ratio with the full-length channel, having 
rise time of 45.8 ±8 ms, 36.9 ±5 ms (p=0.38) and 47.02 ±7 ms (p=0.91) at -120 mV pre-





 and KV10.1+ KV10.1
Δ4−7 
were: 5.9 ±1 ms, 9.12 ±1 ms (p=0.09) and 9.41 ±3 





caused significant deceleration of the 
channel activation after -60 mV conditioning: 257 ±47% (p<0.0001) and 220 ±37% 
(p<0.0001), while at -120 mV the increase of the rise time did not reach statistical 









. Two-electrode voltage clamp recordings: (A) Representative traces of 
KV10.1 activation kinetics after pre-pulse potentials sweeps of -120 mV and -60 mV. (B) Bar graph 









impact on KV1.4-elicited currents 
 










with KV1.4 channel were carried out; 
the same voltage step protocol to study the current-voltage relation previously described 
was applied (Fig. 16 A). KV1.4 is a voltage-gated potassium channel from Shaker-
related subfamily, encoded by KCNA4 gene (Bett and Rasmusson, 2004). Unlike 





 splice isoforms expression did not result in any consistent effect on KV1.4 
current, with the exception of the KV10.1
Δ4−9
 co-expression in 1:10 ratio group, where a 
significant reduction of 37 ±16% (p=0.02) of KV1.4 current at 80 mV was detected (Fig. 




















in 1/10 ratio). Two-electrode voltage clamp recordings: (A) KV1.4 
macroscopic current traces recorded in KV1.4, KV1.4 with KV10.1
Δ4−9
 or with KV10.1
Δ4−7
 samples at 1:1 







effects on KV10.1 currents in a heterologous 
expression system of human origin. 
 
Studies on the impact of KV10.1 splice isoforms on the electrophysiological properties 
of the channel were also performed using a mammalian cell line system: HEK cells 





 fused with the fluorescent protein mVenus. As 
control group, HEK-KV10.1 cells co-transfected with a plasmid containing mVenus 
alone were used. The patch clamp technique under whole cell configuration was the 
method used for recordings of KV10.1 macroscopic currents. Current traces were 
obtained using the following protocol: discrete depolarization pulses between -60 mV 
and +80 mV (in 20 mV increments) of 300 ms length were applied from a holding 
potential of -80 mV (Fig. 17 A). KV10.1 produced slowly activating, outward rectifying 
currents, which did not inactivate; an inward rectification was observed with strong 
depolarizations. This is compatible with a block exerted by intracellular sodium (Pardo 
at al., 1998). The detected steady state current was averaged (between 80% and 90% of 
the time of the depolarization pulse) and normalized by the size of cell membrane 







 co-expression with the full-length channel resulted in a 
marked KV10.1 current reduction of 41.7 ±20.5% (p=0.04) for KV10.1
Δ4−9 
and 53.8 
±21.1% (p=0.01) for KV10.1
Δ4−7 









a human-derived heterologous expression
 
system. Patch clamp experiments: HEK cells expressing 
KV10.1 co-expressing either mVenus (depicted in black), KV10.1
Δ4−9 
mVenus (in green) or KV10.1
Δ4−7 
mVenus (in red). Only green fluorescent cells visualized under epifluorescence microscope were used for 
recordings. (A) Representative current traces. (B) To determine the current-voltage relationship, the 
steady-state current was measured at the end of each pulse and normalized against cell size. (C) Bar graph 
resuming the KV10.1 current density values at +80 mV. 
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voltage dependence of KV10.1, tail current protocols in high extracellular potassium 
were used. The membrane potential was depolarized for 300 ms to a range of voltages 
between +80 and -80 mV in 20 mV decrements, followed by a hyperpolarization step to 
-120 mV for 300 ms (Fig. 18 A). The relative conductance (G/Gmax) values were 
obtained by extrapolating the peak tail current amplitudes for each voltage (as described 
in section 3.4.2 of materials and methods) and normalizing them against the peak tail 
current recorded at +80 mV.  
Normalized current amplitude plotted was against the voltage then fitted with a 
Boltzmann sigmoid function. The resulting Vhalf (voltage of half-maximal activation) 
was 21 ±1.7 mV for KV10.1 control, 23 ±7.3 mV for KV10.1 +KV10.1
Δ4−9
 and 20 ±1.3 
mV, for KV10.1 + KV10.1
Δ4−7
. The slope factor k obtained were 19±1.5 mV, 20 ±3.3 
mV and 19 ±1.2 mV (Fig. 18 B), respectively. In conclusion, no significant changes in 
















. Patch clamp recordings of HEK cells: samples expressing KV10.1 and co-
expressing either mVenus are depicted in black, KV10.1
Δ4−9 
mVenus (in green) or KV10.1
Δ4−7 
mVenus (in 
red). Only green fluorescent cells visualized under epifluorescence microscope were used for recordings. 
(A) Representative KV10.1 tail currents. (B) G-V graph was generated from tail current analyses utilizing 
the Boltzmann function, representing the mean of KV10.1 conductance versus the maximal conductance 
at each voltage step. 
 
 





 co-expression  
 





 are expressed together with the full-length channel may result from altered 
number of channel surface expression (N), changed single channel conductance (I) or 
open probability (Po) or by a combination of these (see equation 3 in materials and 
methods). To distinguish between these possibilities, non-stationary noise analysis was 
performed on excised Xenopus laevis oocyte macropatches in the outside-out 
configuration, in order to quantify single channel conductance i, probability Po at a 
given voltage, as well as the number of channels N in the patch. However, due to the 
tendency of the channels to be clustered on the membrane surface of the cell, the 
detected number of channels in each patch would have a different ratio with the total 
number of channels. This would make pointless to compare or to average N between 
different patches. Therefore, changes in the amount of KV10.1 channel expressed at the 
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will be quantified using a 
biochemical approach (section 4.7). 
Noise analysis recordings were carried out applying to the membrane patch several 
hundreds of depolarizing stimuli to 40 mV. Then the variance of each trace with respect 
to the average trace was determined, and a parabola function was fitted to the current 
against the variance data (Fig. 19 A). The results of the fitting in terms of single channel 
current i showed unaltered values between KV10.1 (985 ±322 fA) and KV10.1 co-
injected with KV10.1
Δ4−7
 (872 ±69 fA, p=0.86, Fig. 19 B) samples, whereas in the case 
of KV10.1
Δ4−9
 co-injection, the single channel currents showed a reduction reaching 
statistical significance (596 ±236 fA, p=0.041, Fig. 19 B). 
The extrapolated open probability at 40 mV did not show significant changes between 
the KV10.1 (47.5 ±17%), KV10.1 co-injected with KV10.1
Δ4−9
 (45.7 ±13%; p=0.94, Fig. 
19 C) and KV10.1 co-expressing KV10.1
Δ4−7
 samples (42 ±15%; p=0.71, Fig. 19 C). The 
lack of changes for ‘i’ and ‘Po’ under co-expression with KV10.1
Δ4−7
 suggest that the 
previously recorded reduction in macroscopic channel both in oocytes and HEK cells 
would be caused by a reduced amount of channel N. On the other hand, the interaction 
of KV10.1
Δ4−9
 with KV10.1 mediating total current I reduction is likely to be related (at 
















single channel current and 
open probability. Non-stationary noise analysis of KV10.1-mediated currents. Variance of several 
hundreds of depolarization pulses at +40 mV was calculated from excised Xenopus laevis oocyte 
macropatches in the outside-out configuration. (A) Representatives plots of the variance versus the mean 
current for KV10.1 (depicted in black), KV10.1+KV10.1
Δ4−9
 (in green) and KV10.1+KV10.1
Δ4−7
 (in red) 
samples, with the corresponding fitting parabola. (B) Bar graph showing the mean single channel current 
‘i’ for each recorded group. (C) Bar graph showing the mean open probability Po for each recorded group. 
 
 





The neurotoxin α-bungarotoxin (BTX) binds with high affinity the nicotinic 
acetylcholine receptor (AChR)(Changeux et al., 1970). Researchers took advantage of 
the fact that BTX can also bind with high affinity a small 13 amino acids peptide that is 
homologous to the binding region of the subunit of AChR (Harel et al., 2001) and 
inserted this sequence (bungarotoxin-binding site, BBS) into AMPA receptor subunits. 
Using fluorescent and biotinylated BTX allowed for specific and quantitative surface 
labeling of the AMPA receptor (Sekine-Aizawa and Huganir, 2004). Kohl and 
coworkers adapted this approach to KV10.1 channels, generating the KV10.1-BBS 
system, a novel tool for quantitative analysis of surface KV10.1 (Kohl et al., 2011; 
Herrmann et al., 2012). In this part of work, we aimed to quantify the surface amount of 
KV10.1 channels utilizing the KV10.1-BBS cells system. Bungarotoxin-biotin labeled 
KV10.1 channels contained in the cell lysates were immobilized on streptavidin-coated 
plates, and a sandwich ELISA was performed. The results of five independent 
experiments are summarized in Fig. 20. Data represent the amount of surface KV10.1 in 




 or pCDNA3-mVenus 
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alone (transfected control), normalized against values of untrasfected cells. No relevant 
difference (p=0.618) was detected between KV10.1
Δ4−7 
(0.96 ±0.07) and the control 
samples (0.91 ±0.06); conversely the amount of membrane-bound KV10.1-BBS resulted 
significantly increased (p=0.015) in case KV10.1
Δ4−9 
was co-expressed with the full-
length channel (1.22 ±0.09). Cells containing the BBS without α-bungarotoxin 
treatments as well as cells not containing the BBS were used as negative controls.  
 
 
Figure 20 KV10.1 surface amount increases in presence of KV10.1
Δ4−9




ELISA experiments: surface KV10.1-BBS amount was quantified for HEK-KV10.1-BBS transfected 
either with pCDNA3 (depicted in black, control group), KV10.1
Δ4−9
 (in green), or KV10.1
Δ4−7 
(in red). The 
presented data are normalized against HEK-KV10.1-BBS untransfected cells values, and are derived from 
five independent experiments.  
 
These results, contrary to what had been hypothesized after noise analysis recordings, 
point against the possibility that KV10.1
Δ4−7 
reduce the amount of surface KV10.1 
channels. However, if we consider that noise analysis takes in account only active 
channels, whereas the bungarotoxin used for our surface KV10.1 quantifications tags all 
the KV10.1 subunits located at the membrane surface, we propose that the factor 
underlying the KV10.1
Δ4-7
-mediated KV10.1 current down-regulation is a reduction in 
the number of active channels situated at the membrane surface. For the same reason, 
the observed increase of KV10.1 surface amount in KV10.1-KV10.1
 Δ4-9
 samples could be 








 organization in native conditions 
 




 in native 





heteromeric complexes with the full-length KV10.1, we performed biochemical assays 
maintaining native conditions, preserving the quaternary structure of the protein 
complexes. Blue Native PAGE (BN-PAGE) experiments were therefore carried out: 





mVenus were subjected to electrophoretic separation 
on native polyacrylamide gel, then blotted on PVDF membrane. Membranes were 
decorated with an anti KV10.1 antibody targeting the C-terminal part of the full-length 




 epitopes. Under 
these conditions, broad bands of apparent molecular weight of approximately 900 kDa 





 samples not containing KV10.1, indicating that also the short isoforms 
are arranged in macrocomplexes of apparent molecular weight of ~900 kDa (Fig. 21 A). 
To determine whether the macro-complexes detected here contained both short and full-
length isoforms, rather than only one of these components, two-dimensional SDS-
PAGE were carried out. With these experiments we could dissociate the components of 
the macro-complexes and separate them according to their molecular weight. In both 
KV10.1+ KV10.1
Δ4−9
 and KV10.1+ KV10.1
Δ4−7
 samples, the 900 kDa complex contained 
full-length monomers of respectively ~140 kDa together with short isoform monomers 
of apparent molecular weight respectively ~90 kDa and ~105 kDa (Fig. 21 B). 
Based on their electrophoretic mobility we propose that in native conditions, full-length 
channel and short isoforms are likely to be assembled in supramolecular complexes, 
probably together with additional proteins. Yet, we are not able to tell whether they are 
organized in homo- or heterotetramers. However, despite our effort to refine the 
experimental conditions, in our experiments we still noticed a consistent amount of 
protein retained into the wells, which could be a sign of incomplete protein 
solubilization (Reisinger and Eichacker, 2007). Improvement in solubilization could 
change the electrophoretic behavior of our protein complexes, helping us to 
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interact with KV10.1 in native conditions. (A) BN-PAGE: ~900 





KV10.1 negative samples; the band at ~150 kDa was unspecific because revealed also in KV10.1 negative 
samples. (B) Two-dimensional SDS-PAGE: the macromolecular complex contained both the full-length 









and full-length KV10.1 
 
The tetramerizing coiled coil (TCC) is a 41 amino acid sequence in KV10.1 C-terminus 
region, responsible for its correct assembling in the tetrameric structure characteristic of 
the functional channel. A leucine to tyrosine mutation at position 20 within this 
sequence (L20Y) has been described to impair the ability of the channel to tetramerize 
and to preclude formation of functional ion channels (Jenke et al., 2003). Here, the 





, and the full length KV10.1. TCC sequence 




 sequences by site 
directed mutagenesis, and the existence of interaction was investigated by means of co-
IP experiments: immunoprecipitation of mVenus protein fused to KV10.1
Δ4−9
 L20Y and 
KV10.1
Δ4−7
 L20Y samples was followed by blotting the membrane with an antibody 





with KV10.1 (protein size ~130 kDa), although in KV10.1
Δ4−9 
immunoprecipitation 
resulted quantitatively less efficient than in KV10.1
Δ4−7
 L20Y samples (Fig. 22). 
 
Figure 22 KV10.1 short isoforms expressing a defective TCC domain coprecipitate with the full-
length channel. Co-IP experiments: immunoprecipitation of mVenus in KV10.1+ KV10.1
Δ4−9
 L20Y and 
KV10.1+ KV10.1
Δ4−7
 L20Y co-precipitated KV10.1 protein (~130 kDa). Input samples consist of 10% (20 
µg) cell extracts. 
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Provided that KV10.1 and short isoforms having altered TCC domain still co-
immunoprecipitate, the KV10.1 electrophysiological properties under co-expression 
with the L20Y splice variants constructs were analyzed with patch clamp recordings in 
the whole cell configuration (Fig. 23 A). Using as reference KV10.1-expressing cells, at 
80 mV voltage, KV10.1 current density was down-regulated by 45.3 ±20.3 % (p=0.03) 
in KV10.1 + KV10.1
Δ4−7
 L20Y samples (Fig. 23 B and C), similarly to prior recordings 
with KV10.1+ KV10.1
Δ4−7
 WT.  
Conversely, in KV10.1 + KV10.1
Δ4−9
 L20Y samples the mild current reduction recorded 
(20.8 ±21.9 %) was not statistically significant compared to the reference group 
(p=0.34, Fig. 23 B and C), in contrast with the outcome of previous electrophysiological 
analysis performed with KV10.1+ KV10.1
Δ4−9
. This result strongly indicates that current 
reduction of KV10.1 requires an intact TCC, therefore suggesting that the TCC sequence 
plays a critical role in the KV10.1
Δ4−9











-L20Y. Patch clamp recordings of HEK cells: cells expressing KV10.1 co-
expressing either mVenus are depicted in black, KV10.1
Δ4−9
-L20Y-mVenus (in green) or KV10.1
Δ4−7
-
L20Y-mVenus (in red). Only green fluorescent cells visualized under epifluorescence microscope were 
used for recordings. (A) Typical KV10.1 current traces. (B) I-V graph representing the mean of KV10.1 
current density at each voltage step. (C) Bar graph resuming the KV10.1 current density values at +80 
mV. 
 
4.9.2 Effects on KV10.1 glycosylation pattern mediated by KV10.1
Δ4−7 
interaction 
with the full-length channel 
 
N-Linked glycosylation is a common post-translational modification of membrane 
proteins. Proper glycosylation is required for correct trafficking of KV10.1 protein to the 
membrane and important for the regular function of the channel already inserted in the 
membrane (Napp et al., 2005). KV10.1 glycosylation pattern (after immunobloting using 
a specific antibody) consists of two distinct bands, with electrophoretic mobilities 
corresponding to ~110 and ~130 kDa (termed E110 and E130). E110 corresponds to 
core glycosylated KV10.1 located in the ER and Golgi, while E130 is a post ER, 
complex glycosylated isoform (Napp et al., 2005). Results from co-IP experiments 
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previously performed showed that under co-expression with KV10.1
Δ4−7
, KV10.1 protein 
presented an altered electrophoretic pattern, compared with KV10.1
Δ4−9
 co-expression 
(Fig. 12 A). We wanted now to determine whether this phenomenon was a result of 
modified glycosylation occurring to KV10.1 under co-expression with KV10.1
Δ4−7
. To 
this aim, we performed an immunoprecipitation with an antibody targeting mVenus, 
then we digested the samples with the enzymes Endo H (removing only core 
oligosaccharides) and PNGase F, (which fully deglycosylates proteins). KV10.1 
glycosylation pattern resulted indistinguishable in both the cases KV10.1 is expressed 
alone or in combination with KV10.1
Δ4−9
. Unlike the previous cases, KV10.1 
glycosylation pattern was changed under co-expression with KV10.1
Δ4−7
: E130 band 
was very faint (Fig. 24 A) in the control lane, and virtually absent in the PNGase F-
treated samples. This would suggest that interaction between the full-length and 
KV10.1
Δ4−7
 occurs when the KV10.1 protein is at immature state and that under these 
conditions its further glycosylation is impaired. The result of this phenomenon is a 
progressive reduction of KV10.1 complex glycosylated fraction in a KV10.1
Δ4−7
 dose-
dependent manner. This is accompanied by a parallel increase of E110 KV10.1 form, as 
resulting from this IP experiment using oocytes injected with different ratios 
KV10.1/KV10.1
Δ4−7














 performed using 
Endo H and PNGase F to highlight the KV10.1 glycosylation pattern. Notice that E130 is virtually absent 
under co-interaction KV10.1-KV10.1
Δ4−7
. (B) Immunoprecipitation of KV10.1 and KV10.1
Δ4−7
 proteins in 
oocytes injected with increasing ratios KV10.1
Δ4−7
-KV10.1. E110/E130 ratio increases together with 
increasing ratios of KV10.1
Δ4−7
/ KV10.1cRNA injected. (C) Densitometric analysis of Fig. 4.16 B: for 









proliferation and cell cycle progression of KV10.1-expressing cells 
 
KV10.1 channels expression and function has been related to cell proliferation (Pardo et 
al., 1999; Weber et al., 2006). Moreover, KV10.1 channel activity is thought to be 
dependent on the cell cycle phase (Meyer and Heinemann, 1998; Camacho et al., 2000). 





and the underlying channel functional reduction lead to consequences in terms of cell 
proliferation and variations in cell cycle distribution. We performed live cell imaging 





. pCDNA3-mVenus was the construct transfected in the cells of the control 
group. A cell confluency mask was created, and the confluency percentage was plotted 
versus the time of culture (analyses always started 5 hours after transfections) (Fig. 25). 
In HEK-KV10.1 cells, the proliferation rate was virtually indistinguishable between 
short isoforms-transfected cells and the control group (data not shown). In SH-SY5Y, 
KV10.1
Δ4−9
 transfected cells showed a mild reduction in proliferation, which peaked (-
8.37%) at about 50 hour after the analysis started, albeit not statistically significant 
(p≥0.608). Similarly, the proliferation rate of the KV10.1
Δ4−7
-transfected cells was 
reduced. The difference was the most prominent at ~60 hour after analysis start (-
18.1%); however this difference was also not statistically significant (p≥0.145). Overall, 















overexpression does not significantly affect the growth rate of 





(red line), or a pCDNA3 empty vector (black line; control 
group). The time interval between each measurement is 4 hours. 
 
We also evaluated the cell cycle distribution of KV10.1 expressing cells, under co-




. To this aim 
we stained the cells’ DNA with Pi and performed flow cytometry experiments. Both 





cells (CHO-KV10.1 cells) were used in these experiments 
(Fig. 26). No evident changes in the fraction of cells retained in different cell cycle 
phases were observed in any of the cell lines investigated. 
 
 




does not alter the cell cycle profile of CHO-
KV10.1 and SH-SY5Y cells. The fraction of cells in G0/G1 is depicted in black; cells in S phase are in 






The general aim of the present thesis work has been to study the impact of alternative 
splicing on KV10.1 biological properties, by first confirming the expression of KV10.1 
short isoforms in native system, and then studying the mechanisms and consequences of 
interaction in detail. We started providing direct evidence of E65 and E70 expression in 
native systems. Both of the short isoforms coprecipitated and colocalized with KV10.1 
full-length channel in a reconstituted system. Remarkably, E65 and E70 also occurred 
together with the full-length channel in the same supramolecular complex in native 
conditions. A robust down-regulation of ion currents through KV10.1 channels was 
observed when KV10.1 was co-expressed with E65 and E70. The modulation is dose-
dependent and most likely specific to KV10.1 channels, since there was generally no 
effect on KV1.4 current properties. Possible mechanisms underlying E65- and E70- 
induced current down-regulation were also investigated. The two short isoforms seem to 
affect KV10.1 function through different mechanisms. In the case of E65 the TCC, 
although not required for the interaction between the two proteins, seems to play a 
critical role in the modulation of KV10.1 current amount. On the other hand E70 
expression impaired the glycosylation of KV10.1 channels and was independent of TCC; 
this would probably result in the production of ‘immature’ ion channels which, although 
capable of reaching the membrane, would be defective in terms of function. 
 
 
5.1 KV10.1 short isoforms are expressed in normal brain and cell lines from diverse 
origins 
 
E65 and E70 are non-channel proteins recently identified in our laboratory that are 
derived from alternative spliced KV10.1 voltage-gated potassium channels. By PCR 
analysis, E70 was found in human brain (Pardo LA, unpublished data) and in the 
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melanoma cell line IPC 298 (Ramos Gomes PhD thesis, 2010), while E65 was isolated 
IGR 39, another melanoma cell lines.  
It was crucial to confirm that the expression of the splice variants was not due to 
artifacts derived from DNA amplification. This was achieved using the nuclease 
protection assay (Cocquet et al., 2006; Roy and Irimia, 2008). E65 expression was 
found in IGR 39 melanoma cell lines (experiments performed by Dr. Ramos Gomes) 
whereas E70 was detected in the neuroblastoma cell lines IMR 32 and SH-SY5Y (Fig. 
11). Nuclease protection assay (RPA) did not confirm the expression of E70 previously 
detected with nested PCR in IPC 298 cells 
Nested PCR experiments were also carried out in a panel of cancer as well as non-
cancer cell lines (see table 6). The outcome matched with the result of RPA 
experiments, and moreover suggested that expression of short isoforms is not limited to 
cancer cells, since E65 was detected in the prostate epithelium cells and E70 was found 
in human brain. Presumably, E65 and E70 expression does not derive from cancer-
specific events driving alternative splicing. E65 and E70 production would rather be the 
result of a conserved splicing mechanism occurring in both physiological and 
pathological scenarios.  
Unfortunately, expression of E65 and E70 could not be quantitatively measured by real-
time PCR analysis. Specifically designed E65/E70 primers and TaqMan probes showed 
high sensitivity towards plasmid DNA as a template (Fig. 10), but could not detect the 
splice variants in cells natively expressing the short isoforms. PCR in general is a very 
sensitive technique (10-50 copies mRNA target represent a realistic detection limit 
(Piatak et al., 1993)), but the relative sensitivities of nested and real-time PCR are under 
dispute. Some reports claim that real-time PCR sensitivity is equivalent or even superior 
to nested PCR (Drago et al., 2004; Kawada et al., 2004; Kim et al., 2008), but others 
conclude the opposite (Elmaagacliet al., 2000; Guo et al., 2002; Takenokuchi et al., 
2004). In agreement with the latter reports, in this work we could successfully amplify 
E65 and E70 with nested PCR, but not with real-time PCR.  
We successfully detected both isoforms in RPA assays, which have a detection limit of 
~10
5 
transcript copies (Foley et al., 1993), much less sensitive than PCR techniques. 
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However, the amount of template used for RPA was ~400 times higher (80 µg) that for 
PCR (~200 ng), and therefore sensitivities cannot be compared.  
In accordance with the scarce E65 and E70 transcripts expression, we did not detect the 
presence of bands of molecular weight compatible with the predicted 65 and 70 kDa by 
western blot in natively expressing systems, although they were detected in lysates from 
cells overexpressing constructs encoding both the KV10.1 short isoforms. 
The scant E65 and E70 expression levels in the heterogeneous cell population can be 
due to low expression levels in a majority of cells, but also to a higher level in a 
restricted subpopulation. In this regard, AS regulation driving E65 and E70 expression 
could be a time-selective process, depending on a particular phase of cell cycle, or 
triggered by defined transcription factors or protein modifications. Interestingly, full-
length KV10.1 channel expression is selectively regulated along the cell cycle, as 
initially described (Meyer and Heinemann, 1998; Pardo et al., 1998; Camacho et al., 
2000), and more recently by Urrego Blanco from our research group (Urrego Blanco 
PhD thesis, 2014)). Therefore it is conceivable that E65 and E70 expression could also 
be cell cycle-dependent. This would not be unique for KV10.1, because the AS pattern 
of CaV3.1 and KV11.1 (which belongs to the eag family) channels changes during 
differentiation of neuroblastoma cells (Crociani et al., 2003; Bertolesi et al., 2006). We 
tested this hypothesis by synchronizing cells natively expressing KV10.1 at the G1/S 
boundary of the cell cycle using the double thymidine block strategy (Prescott et al., 
1971): we noticed changes in E65 and E70 expression pattern along the cell cycle (data 
not shown). However, since we were forced to use the nested PCR technique (see 
above), the quantification was arduous and we could draw no conclusive statement 
regarding this assumption. 
In a recent publication, Sun and coworkers reported that calcium influx (mediated by 
ionomycin) or activation by either PKA or PKC (Sun et al., 2009) stimulate the 
production of a short isoform of D-Eag1, the KV10.1 ortholog in Drosophila. 
Importantly, this truncated splicing isoform was generated from cDNA of the full-
length channel transfected in mammalian cells, not from genomic DNA in a native 
system. We tested if a similar mechanism takes place in mammalian cells transfected 
with full-length KV10.1 and in cells natively expressing E65 and E70. Ionomycin 
treatment or stimulation of protein kinase A and C failed to increase transcript 
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expression, and no E65 or E70 proteins were observed (data not shown). However, it 
has to be kept in mind that for E65 and E70 transcripts analysis we have to deal with the 
limitation of nested PCR technique, which is not meant to be a quantitative assay and 
therefore we may have missed subtle expression changes. 
Further investigation will be required to elucidate the factor(s) triggering KV10.1 short 
isoforms expression. This would certain benefit from the comprehension of E65 and 
E70 physiological and pathophysiological functions.  
 
 
5.2 E65 and E70 interact with KV10.1 channel and modulate its function 
 
AS is emerging as a mechanism for the modulation of ion channel function. There are 
several cases where interaction occurs between functionally inactive splice isoforms and 
the correspondent full-length ion channel. This is usually associated with modulation of 
current flow, leading to a dominant negative-effect on current amplitude (Kupershmidt 
et al., 1998; Chu et al., 2005; Guasti et al., 2008; Veale et al., 2010; Wagner et al., 2010; 
Ohya et al., 2011; Bidaux et al., 2012). 
Here we show for the first time that both non-conducting E65 and E70 splice isoforms 
interact with full-length KV10.1 channels (Fig. 12 and 13) and modulate KV10.1 current 
amplitude (Fig. 14 and 17), in a dose-dependent manner (Fig. 14). KV10.1 current 
undergoes a mild voltage dependent inward rectification in all our recordings. Such a 
phenomenon appears to be exacerbated upon co-expression with splice variants. This is 
yet another consequence of the functional modulation mediated by the short isoforms on 
the full-length channel. Rectification can be caused by at least two different processes 
(Hille, 2001). In some channels, it is caused by soluble factors blocking the pore, such 
as Mg
2+
 or polyamines. In others, the rectification is directly caused by voltage- and/or 
state-dependent conformational changes of the channel. A member of the eag family, 
KV11.1, undergoes the latter rectification mechanism (Schönherr and Heinemann, 1996; 
Smith et al., 1996; Spector et al., 1996). KV10.1 channels expressed in Xenopus laevis 





ions), although this phenomenon is restricted upon onset of maturation 
(Pardo et al., 1998). 
The current modulation by E65 and E70 seems restricted to KV10.1 channel since the 
expression of either short isoform did not affect the activity of KV1.4 voltage-gated 
potassium channels, albeit E65/KV1.4 injected oocytes (at 10:1 ratio) significantly 
decreased the current through KV1.4 (Fig. 16). However, E65 is capable of inducing 
maturation of Xenopus laevis oocytes (Ramos Gomes, PhD thesis, 2010). Moreover, 
current flowing through potassium channels can be altered depending on the cell cycle 
phase: apart from the already mentioned case of KV10.1, this phenomenon has been 
observed in KV11.1 and KV1.3 channels (Arcangeli et al., 1995; Chittajallu et al., 2002). 
It is therefore conceivable that the maturation triggered by E65 may account for the 
effect on KV1.4 current, without the need of a direct interaction between E65 and KV1.4. 
Nonetheless, it has been reported that the KV1.4 current amplitude does not dramatically 
change upon oocyte maturation (Brüggemann et al., 1997). 
KV10.1 activation kinetics were slowed down by an excess (10:1) of either isoform (Fig. 
15). Mutations induced in both intracytoplasmic PAS and cNBD domain sequences of 
KV10.1 channel also result in decelerated activation kinetics (Stevens et al., 2009). 
Furthermore, it has been recently described that in the KV10.1 crystal structures the 
cNBD and PAS domains interact extensively. Destabilizing the molecular bridge 
connecting these two regions also affects gating of the channel, resulting in slower 
activation kinetics (Haitin et al., 2013). Thus, one possibility would be that E65 and E70 
expression at high concentration affect the canonical KV10.1 channel intracytoplasmic 
folding, modifying the cNBD/PAS domain interaction and affecting the channel 
activation kinetics. 
Further electrophysiological analyses have been carried out to understand the 
determinant(s) underlying the reduction in KV10.1 current amplitude induced by the 
splice variants. Changes in voltage dependence have been excluded (Fig. 18). Total 
current I flowing through ion channels in a membrane is the product of the number of 
channels expressed on the plasma membrane N, the channel unitary conductance i, and 
open probability Po (see equation 3). Noise analysis revealed that Po was not 
significantly affected upon co-expression of KV10.1 with E65, whereas single channel 
current i was reduced by ~40% (Fig. 19). This would explain the ~42% reduction in 
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total current amplitude I that this short isoform exerts on KV10.1 current, albeit surface 
KV10.1 was significantly increased upon co-expression KV10.1-E65 (Fig. 20). i and Po 
values were unaltered by co-expression of E70, indicating a reduced amount of surface 
KV10.1. Biochemical binding assays did not corroborate with the assumption of a 
reduced KV10.1 surface expression in E70 expressing samples. 
However, regarding the method used to measure the surface KV10.1, although we know 
that the stoichiometry of bungarotoxin binding to the BBS of each KV10.1 monomer is 
1:1, we cannot exclude the possibility that steric hindrance would allow only one 
bungarotoxin-biotin molecule binding to the KV10.1 tetramer. Therefore, since the BBS 
is only present in KV10.1, and not in E65 or E70, if the latter two
 
form heteromultimers 
with the full-length channel, we could still quantify them with the α-bungarotoxin 
approach, being unable to distinguish between homotetramers of full-length channel and 
heteromers with short isoforms. The heteromers are most likely functionally inactive, 
and not measured by noise analysis recordings. Functionally defective channels arising 
from a scenario where E65 and E70 would lock the membrane surface KV10.1 in a 
functionally inactive state without necessarily heterotetramerize would also be 
measured by our biochemical binding assay, whereas not counted by noise analysis 
recordings. Ultimately, if we consider that noise analysis takes in account only active 
channels, whereas the bungarotoxin used for our surface KV10.1 quantifications tags all 
KV10.1 surface channel subunits, we infer that the reduction in the number of active 
channels situated at the membrane surface is the factor underlying the E70-mediated 
KV10.1 current down-regulation.  
Unlike what observed with E70, E65 co-expression with KV10.1 results in diminished 
single channel current i. Moreover, the detected increase in surface expression of 
KV10.1 subunits could be due to simultaneous effect of this splice variant on trafficking 
and/or turnover rate of the full-length. 
Recapitulating, each of the two short isoforms would achieve the same effect (reducing 
the Kv10.1 current amplitude) through a different mechanism of action: E65 expression 
would mainly diminish the KV10.1 single channel current, while E70 may render a 
fraction of channels locked in a non-conducting state. 
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Both E65 and E70 isoforms occur in the same supramolecular complex together KV10.1 
full-length, as deduced from membrane-enriched extracts in native conditions (Fig. 21). 
This supports our assumption that each of the short isoforms interacts with the full-
length at the plasma membrane. Moreover it suggests that E65/KV10.1 and E70/KV10.1 
could be components of a bigger macromolecular complex in native conditions. 
Additional KV10.1 interaction partners have been identified. The K
+ 
channel regulator 1 
(KCR1) is a plasma membrane-associated protein binding to the C-terminal region of 
the rat KV10.1, modulating its electrophysiological properties (Hoshi et al.,1998). 
Rabaptin-5 is a binding partner KV10.1, crucial for trafficking (Ninkovic et al., 2012). 
Cortactin is an actin-interacting protein implicated in cytoskeletal architecture, binding 
the KV10.1 C-terminus and modulating the channel’s surface expression (Herrmann et 
al., 2012). Moreover, Hsu and co-workers reported that 14-3-3θ, which belongs to a 
family of proteins abundantly expressed in the brain and implicated in the modulation of 
several neuronal processes, is a binding partner of the rat KV10.1 channel. Both the N- 
and C-termini of the channel are required for association with 14-3-3θ. Co-expression 
of 14-3-3θ with KV10.1 reduces current amplitude. Interestingly, no apparent alteration 
of the steady-state voltage dependence, gating kinetics, single channel conductance or 
changes in surface protein level or membrane trafficking were detected (Hsu et al., 
2012). This scenario strongly resembles what we observed for E70. 
Speculating about the molecular association between full-length and short isoforms, one 
of the possibilities would imply heterotetramerization between full-length and short 
isoforms. Heterotetramerization is a rather common phenomenon among ion channels, 
also involving voltage-gated potassium channels (Pongs, 1992). Furthermore, both E65 
and E70 retain the TCC domain (situated within the C-terminal sequence), critical for 
channel tetramerization (Jenke et al., 2003; Ludwig et al., 1997). However, despite the 
presence of these elements, we tend to exclude that heterotetramerization between full-
length and short isoforms is taking place for the following reasons. Coiled coils (whose 
formation underlies tetramerization) are protein-protein interaction domains having a 
helical arrangement consisting in repetition of a heptad structural motif (abcdefg), 
where the positions a and d are preferably occupied by hydrophobic amino acids 
(Lupas, 1996). The lack of hydrophobic region within the splice variants sequences 
would make the heterotetramer formation energetically unfavorable, as well as result in 
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functionally inactive channels, because all four subunits must contribute to form the 
pore, and therefore mutations in the pore are dominant-negative (Kuzhikandathil and 
Oxford, 2000). Furthermore, TCC-defective E65 and E70 short isoforms conserve the 
interaction with KV10.1 (Fig. 22), ruling out the occurrence of heterotetramerization 
between short isoforms and full-length channel. Consequently, the interaction between 
short isoforms and KV10.1 would occur by means of interaction site(s) across the N- 
and/or C-termini regions, which are mostly conserved in the splice variants and full-
length channels.  
 
 
5.3 Involvement of the TCC domain in the modulation of KV10.1 channels by E65  
 
We suppose that co-expression of E65 with KV10.1 causes a reduction of single channel 
conductance leading to a current amplitude reduction. Additionally, results from the 
measurement of the surface KV10.1 subunits, together with the ones from the analysis of 
further KV10.1 biophysical properties, suggest that under E65 co-expression a fraction 
of functionally inactive KV10.1 channels could be produced (as also observed in the 
context of E70 co-expression with KV10.1). 
Moreover, we have evidence strongly suggesting that TCC domain is accounting for the 
observed functional modulation: E65 bearing a TCC domain defective in its ability to 
tetramerize (mutation L20Y) (Jenke et al., 2003) fails to diminish KV10.1 current 
amplitude (Fig. 23), in contrast to co-expression with the E65 WT. To our knowledge, 
this is the first case in which a channel function alteration mediated by a non-conductive 
splicing isoform is associated to a specific domain. 
E65 L20Y co-precipitates with the full-length KV10.1 (Fig. 22). This implies that 
occurrence of physical interaction per se is not sufficient to trigger E65-mediated 
functional modulation of KV10.1 current. As previously mentioned, KV10.1 voltage 
dependent inward rectification in all our recordings was augmented when KV10.1 was 
expressed together with the short isoforms. However, this phenomenon was conserved 
upon co-expression of L20Y splice variants (also in E65 L20Y, where KV10.1 current 
down-regulation is virtually absent). This suggests that the voltage-dependent 
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rectification may be linked to the physical interaction between splice variants and full-




5.4 Altered KV10.1 glycosylation could explain the modulation of KV10.1 channels 
by E70   
 
Based on experiments, we propose that E70 modulates KV10.1 by rendering a fraction 
of KV10.1 channels non-conductive (this may occur also for E65). How could E70 exert 
this action? Our data provides a possible answer: E70 coprecipitates prevalently with an 
immature glycosylated form of KV10.1 (Fig. 24 A) and its expression diminishes the 
ratio of complex glycosylated to core glycosylated KV10.1  in a dose-dependent manner 
(Fig. 24 B and C). The relevance of glycosylation of KV10.1 channels has been 
exhaustively investigated in a previous report from our lab. Interestingly, a KV10.1 
mutant unable to undergo complex glycosylation (N406Q) showed dramatically reduced 
current amplitude and decelerated activation kinetics (Napp et al., 2005). This 
resembles the electrophysiological behavior of KV10.1 channels co-expressed with E70. 
However, unlike what we observe in KV10.1/E70 cells, N406Q also exhibits a 
dramatically reduced surface expression. The latter does not appear to be a general rule: 
complex N-glycosylation is not required for surface expression of Trpm4b channel 
(Woo et al., 2013), KCa1.1 (Pabon et al., 2000), KV1.1 (Deal et al., 1994) and KV11.1 
(Gong et al., 2002). Altered glycosylation may also reduce the stability of KV10.1 and 
KV11.1 channels, increasing their turnover rate (Napp et al., 2005; Gong et al., 2002). 
Based on our data, we cannot exclude the occurrence of the latter phenomenon upon co-
expression of KV10.1 with E70.  
Endogenous KV10.1 channels enter the synapses of hippocampal neurons by lateral 
diffusion (Gómez-Varela et al., 2010). Moreover KV10.1 channels partition to different 
membrane subdomains, and this affects current amplitude (without any noticeable 
effects on other biophysical parameters) (Jiménez-Garduño et al., 2014). In this 
scenario, E70 expression could modulate KV10.1 function by influencing membrane 
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5.5 Possible physiological role of KV10.1 splice variants  
 
Potassium channels are implicated in diverse physiological and pathophysiological 
processes. Cell cycle and proliferation, cell migration, invasion and apoptosis are all 
processes that can be modified by the expression of potassium channels (Pardo and 
Stühmer, 2014). KV10.1 has been extensively studied in this context since it displays 
oncogenic properties: cells expressing KV10.1 have in general increased proliferation 
rate and its down-regulation reduces proliferation. Indeed, KV10.1 blockade mediated 
by astemizole and siRNA reduces tumor cell proliferation both in vitro (Ouadid-
Ahidouch et al., 2001; Gavrilova-Ruch et al., 2002; Weber et al., 2006) and in vivo 
(Downie et al., 2008).  
RNA interference represents a potent tool to disclose the function of a specific gene. For 
this reason, siRNA sequences specifically targeting E65 and E70 have been designed to 
down-regulate the short isoforms. The only primary sequence differences between full-
length and splice variants lie in the boundary between exon three and ten (for E65) and 
exon three and eight (for E70). This limitation adds to the notorious difficulties for the 
design of an optimal siRNA. Nevertheless, we failed to successfully knock-down the 
splice variants transcript levels (real-time PCR using overexpressing models, data not 
shown).  
Given these issues with RNA interference methods, we set to gain insights into the E65 
and E70 function investigating the effects of their overexpression. In particular, since 
reduction in KV10.1 channel activity decreases cell proliferation, it is conceivable that 
also short isoforms could reduce cell proliferation by diminishing currents through 
KV10.1 channels. We tested this hypothesis using KV10.1 expressing cells that 
simultaneously overexpress the short isoforms. We did not observe any statistically 
significant reduction of cell proliferation in E65- nor in E70- transfected cells (Fig. 25). 
However, low transfection efficiency of the E65 and E70 constructs could account for 
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the lack of effect on cell proliferation. In this regard, generation of stable cell lines co-
expressing short isoforms and full-length channels will help to clarify this issue. 
Remarkably, it has been recently found that E65 directly activates the maturation of 
Xenopus laevis oocytes, suggesting a role in cell cycle regulation for this splicing 
isoform (Ramos Gomes Ph.D. thesis, 2010). However, we did not detect obvious 
changes in cell cycle profile of cells transfected with either E65 or E70 (Fig. 26). 
In conclusion, in this study we undoubtedly confirmed the concomitant expression of 
E65 and E70 with KV10.1, and we further identified mechanism involved in their 
modulation of KV10.1 function. However, more studies will be required in order to 
unravel the physiological and pathophysiological significance of the E65 and E70 splice 
variants. So far, the lack of specific knock-downs and pharmacological tools restricted 
our ‘arsenal’ of methods. Future improvement of the techniques available to manipulate 
and quantitatively detect the splice variants expression will certainly help to further 





















In the past few years, several publications highlighted the role of alternative splicing as 





) represent two recently identified non-channel proteins 
derived from alternative splicing of KV10.1 voltage-gated potassium channels. The two 
short isoforms were identified with PCR techniques and their physiological significance 
was largely obscure.  
This thesis work primarily aimed at studying the impact of E65 and E70 on KV10.1 
properties. 
Firstly, the expression of KV10.1 short isoforms in native system was definitely 
demonstrated by means of nuclease protection assays. Afterwards, occurrence of 
interaction between both E65 and E70 with KV10.1 was investigated: the two splice 
isoforms coprecipitated and colocalized with the KV10.1 full-length channel in a 
reconstituted system. Remarkably, E65 and E70 also occurred together with the full-
length channel in the same supramolecular complex in native conditions. A robust 
down-regulation of ion currents through KV10.1 channels was observed when KV10.1 
was co-expressed with E65 and E70. The modulation was dose-dependent and most 
likely specific to KV10.1 channels, since there were generally no effects on KV1.4 
current. The two short isoforms affect the KV10.1 function through different 
mechanisms. In the case of E65, the TCC domain, although not required for the 
interaction between the two proteins, seems to play a critical role in the modulation of 
KV10.1 current. On the other hand E70 co-expression with the full-length channel 
impairs glycosylation of KV10.1; this would probably result in the production of 
‘immature’ ion channels that, although capable of reaching the membrane, would be 
defective in terms of function. 
KV10.1 channels expression has been implicated in physiological and 
pathophysiological processes like cell proliferation, cell cycle and cancerogenesis. It 
was finally investigated whether E65 and E70 could also be involved in cell 
proliferation and cell cycle modulation. No obvious alterations of cell cycle profile and 
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growth rate of KV10.1-expressing cells were observed under overexpression of E65 or 
E70. 
In conclusion, this study unequivocally demonstrated the expression of E65 and E70 in 
natively expressing systems and provided mechanistic insights into their modulation of 
KV10.1 channel function; yet further studies will be required in order to unravel the 
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